



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 31/54		A1	(11) International Publication Number: WO 97/15308
(21) International Application Number: PCT/US96/17019			(43) International Publication Date: 1 May 1997 (01.05.97)
(22) International Filing Date: 23 October 1996 (23.10.96)			(74) Agents: MURASHIGE, Kate, H. et al.; Morrison & Foerster L.L.P., 2000 Pennsylvania Avenue, N.W., Washington, DC 20006-1888 (US).
(30) Priority Data: 60/005,830 23 October 1995 (23.10.95) US			(81) Designated States: AL, AM, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, FI, GE, HU, IL, IS, JP, KG, KP, KR, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(71) Applicants: ZYMOGENETICS, INC. [US/US]; 1201 Eastlake Avenue East, Seattle, WA 98102 (US). OSTEOSCREEN, INC. [US/US]; Suite 201, 2040 Babcock Road, San Antonio, TX 78229 (US). UNIVERSITY OF TEXAS AT AUSTIN [US/US]; Austin, TX (US).			Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(72) Inventors: PETRIE, Charles; 18459 N.E. 196th Place, Woodinville, WA 98072 (US). ORME, Mark, W.; 636 N.W. 98th Street, Seattle, WA 98117 (US). BAINDUR, Nand; 13919 57th Place West, Edmonds, WA 98026 (US). ROBBINS, Kirk, G.; 1200 Grant Avenue South #Y-304, Renton, WA 98055 (US). HARRIS, Scott, M.; 6825 31st Avenue N.E., Seattle, WA 98815 (US). KONTOYIANNI, Maria; 769 Hayes Street #504, Seattle, WA 98109 (US). HURLEY, Laurence, H.; 5915 Northwest Place, Austin, TX 78731 (US). KERWIN, Sean, M.; 703 Ivy Court, Round Rock, TX 78681 (US). MUNDY, Gregory, R.; 3719 Morgan's Creek, San Antonio, TX 78230 (US).			
(54) Title: COMPOSITIONS AND METHODS FOR TREATING BONE DEFICIT CONDITIONS			
(57) Abstract			
Compounds containing two aromatic systems covalently linked through a linker containing one or more atoms, or "linker" defined as including a covalent bond <i>per se</i> so as to space the aromatic systems at a distance 1.5-15Å, are effective in treating conditions associated with bone deficits. The compounds can be administered to vertebrate subjects alone or in combination with additional agents that promote bone growth or that inhibit bone resorption. They can be screened for activity prior to administration by assessing their ability to effect the transcription of a reporter gene coupled to a promoter associated with a bone morphogenetic protein and/or their ability to stimulate calvarial growth in model animal systems.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

COMPOSITIONS AND METHODS FOR TREATING BONE DEFICIT CONDITIONS

Technical Field

5 The invention relates to compositions and methods for use in limiting undesired bone loss in a vertebrate at risk of such bone loss, in treating conditions that are characterized by undesired bone loss or by the need for bone growth, in treating fractures, and in treating cartilage disorders. More specifically, the invention concerns the use of specific classes of compounds identified or characterized by a high throughput screening assay.

Background Art

Bone is not a static tissue. It is subject to constant breakdown and resynthesis in a complex process mediated by osteoblasts, which produce new bone, and osteoclasts, which 15 destroy bone. The activities of these cells are regulated by a large number of cytokines and growth factors, many of which have now been identified and cloned. Mundy has described the current knowledge related to these factors (Mundy, G.R. *Clin Orthop* 324:24-28, 1996; Mundy, G.R. *J Bone Miner Res* 8:S505-10, 1993).

Although there is a great deal of information available on the factors which 20 influence the breakdown and resorption of bone, information on growth factors which stimulate the formation of new bone is more limited. Investigators have searched for sources of such activities, and have found that bone tissue itself is a storehouse for factors which have the capacity for stimulating bone cells. Thus, extracts of bovine bone tissue obtained from slaughterhouses contain not only structural proteins which are responsible 25 for maintaining the structural integrity of bone, but also biologically active bone growth factors which can stimulate bone cells to proliferate. Among these latter factors are transforming growth factor β , the heparin-binding growth factors (acidic and basic fibroblast growth factor), the insulin-like growth factors (insulin-like growth factor I and insulin-like growth factor II), and a recently described family of proteins called bone 30 morphogenetic proteins (BMPs). All of these growth factors have effects on other types of cells, as well as on bone cells.

- The BMPs are novel factors in the extended transforming growth factor β superfamily. They were first identified by Wozney J. *et al. Science* (1988) 242:1528-34, using gene cloning techniques, following earlier descriptions characterizing the biological activity in extracts of demineralized bone (Urist M. *Science* (1965) 150:893-99).
- 5 Recombinant BMP2 and BMP4 can induce new bone formation when they are injected locally into the subcutaneous tissues of rats (Wozney J. *Molec Reprod Dev* (1992) 32:160-67). These factors are expressed by normal osteoblasts as they differentiate, and have been shown to stimulate osteoblast differentiation and bone nodule formation *in vitro* as well as bone formation *in vivo* (Harris S. *et al. J. Bone Miner Res* (1994) 9:855-63). This latter
- 10 property suggests potential usefulness as therapeutic agents in diseases which result in bone loss.

The cells which are responsible for forming bone are osteoblasts. As osteoblasts differentiate from precursors to mature bone-forming cells, they express and secrete a number of enzymes and structural proteins of the bone matrix, including Type-1 collagen, 15 osteocalcin, osteopontin and alkaline phosphatase (Stein G. *et al. Curr Opin Cell Biol* (1990) 2:1018-27; Harris S. *et al. (1994), supra*). They also synthesize a number of growth regulatory peptides which are stored in the bone matrix, and are presumably responsible for normal bone formation. These growth regulatory peptides include the BMPs (Harris S. *et al. (1994), supra*). In studies of primary cultures of fetal rat calvarial 20 osteoblasts, BMPs 1, 2, 3, 4, and 6 are expressed by cultured cells prior to the formation of mineralized bone nodules (Harris S. *et al. (1994), supra*). Like alkaline phosphatase, osteocalcin and osteopontin, the BMPs are expressed by cultured osteoblasts as they proliferate and differentiate.

Although the BMPs are potent stimulators of bone formation *in vitro* and *in vivo*, 25 there are disadvantages to their use as therapeutic agents to enhance bone healing. Receptors for the bone morphogenetic proteins have been identified in many tissues, and the BMPs themselves are expressed in a large variety of tissues in specific temporal and spatial patterns. This suggests that BMPs may have effects on many tissues other than bone, potentially limiting their usefulness as therapeutic agents when administered 30 systemically. Moreover, since they are peptides, they would have to be administered by injection. These disadvantages impose severe limitations to the development of BMPs as therapeutic agents.

- There is a plethora of conditions which are characterized by the need to enhance bone formation. Perhaps the most obvious is the case of bone fractures, where it would be desirable to stimulate bone growth and to hasten and complete bone repair. Agents that enhance bone formation would also be useful in facial reconstruction procedures. Other 5 bone deficit conditions include bone segmental defects, periodontal disease, metastatic bone disease, osteolytic bone disease and conditions where connective tissue repair would be beneficial, such as healing or regeneration of cartilage defects or injury. Also of great significance is the chronic condition of osteoporosis, including age-related osteoporosis and osteoporosis associated with post-menopausal hormone status. Other conditions 10 characterized by the need for bone growth include primary and secondary hyperparathyroidism, disuse osteoporosis, diabetes-related osteoporosis, and glucocorticoid-related osteoporosis. In addition, or alternatively, the compounds of the present invention may modulate metabolism, proliferation and/or differentiation of normal or aberrant cells or tissues.
- 15 There are currently no satisfactory pharmaceutical approaches to managing any of these conditions. Bone fractures are still treated exclusively using casts, braces, anchoring devices and other strictly mechanical means. Further bone deterioration associated with post-menopausal osteoporosis has been decreased or prevented with estrogens or bisphosphonates.
- 20 US Patent 5, 280, 040 discloses a class of compounds which are 3, 4-diaryl chromans. These compounds can be considered derivatives of 2,3,4 triphenyl butanol, where the hydroxy at the 1-position forms an ether with the ortho position of the phenyl group substituted at the 4-position of the butanol. The parent 3,4-diaryl chromans do not contain nitrogen atoms in the aromatic moieties or their linkers. A preferred compound, 25 centchroman, contains a nitrogen substituent only in one of the substituents on a phenyl moiety. These compounds are disclosed in the '040 patent as useful in the treatment of osteoporosis.
- The present invention discloses compounds useful for limiting or treating bone deficit conditions, and for other uses that should be apparent to those skilled in the art from 30 the teachings herein.

Disclosure of the Invention

The invention provides compounds that can be administered as ordinary pharmaceuticals and have the metabolic effect of enhancing bone growth. The compounds of the invention can be identified using an assay for their ability to activate control elements associated with these factors. Thus, the invention is directed to methods and compositions for stimulating the growth of skeletal (bone) tissue, which methods and compositions use, as active ingredients, compounds wherein two aromatic systems are coupled so as to be spaced apart from each other by about 1.5 to about 15 Angstroms. The thus-linked systems (including the linker coupling them) may include at least one nitrogen atom other than a ring substituent.

Therefore, the compounds useful in the invention can be described as having the formula Ar¹-linker-Ar², wherein each of Ar¹ and Ar² is independently an aromatic system and the linker portion of the formula spaces Ar¹ and Ar² apart by a distance of approximately 1.5-15 Angstroms. Ar¹, Ar² and the linker may optionally be substituted with non interfering substituents. In the useful compounds, there may be at least one nitrogen atom in either Ar¹, Ar² and/or the linker, independent of any substituents thereon. Preferably, the compounds of the invention also contain at least one additional heteroatom selected from the group consisting of N, S and O, independent of any substituent.

Other compounds of the invention include particular five membered rings having charge separation.

Thus, the invention is directed to methods to treat bone disorders using the compounds described and to pharmaceutical compositions for this use.

Brief Description of the Drawings

Figure 1 shows the dose response curve for the compound, designated 59-0008. Figures 2 and 3 show illustrative compounds of the invention and the results obtained with them in an *in vitro* test.

Modes of Carrying Out the Invention

A rapid throughput screening test for compounds capable of stimulating expression of a reporter gene linked to a BMP promoter (a surrogate for the production of bone morphogenetic factors that are endogenously produced) is described in U.S. Application

Serial No. 08/458,434, filed 2 June 1995, the entire contents of which are incorporated herein by reference. This assay is also described as a portion of a study of immortalized murine osteoblasts (derived from a mouse expressing a transgene composed of a BMP2 promoter driving expression of T-antigen) in Ghosh-Choudhery, N. *et al. Endocrinology*

5 (1996) 137:331-39. In this study, the immortalized cells were stably transfected with a plasmid containing a luciferase reporter gene driven by a mouse BMP2 promoter (-2736/114 bp), and responded in a dose-dependent manner to recombinant human BMP2.

Briefly, the assay utilizes cells transformed permanently or transiently with constructs in which the promoter of a bone morphogenetic protein, specifically BMP2 or 10 BMP4, is coupled to a reporter gene, typically luciferase. These transformed cells are then evaluated for the production of the reporter gene product; compounds that activate the BMP promoter will drive production of the reporter protein, which can be readily assayed. Over 40,000 compounds have been subjected to this rapid screening technique, and only a very small percentage are able to elicit a level of production of luciferase 5-fold greater 15 than that produced by vehicle. Compounds that activate the BMP promoter share certain structural characteristics not present in inactive compounds. The active compounds ("BMP promoter-active compounds" or "active compounds") are useful in promoting bone or cartilage growth, and thus in the treatment of vertebrates in need of bone or cartilage growth.

20 BMP promoter-active compounds can be examined in a variety of other assays that test specificity and toxicity. For instance, non-BMP promoters or response elements can be linked to a reporter gene and inserted into an appropriate host cell. Cytotoxicity can be determined by visual or microscopic examination of BMP promoter- and/or non-BMP promoter-reporter gene-containing cells, for instance. Alternatively, nucleic acid and/or 25 protein synthesis by the cells can be monitored. For *in vivo* assays, tissues may be removed and examined visually or microscopically, and optionally examined in conjunction with dyes or stains that facilitate histologic examination. In assessing *in vivo* assay results, it may also be useful to examine biodistribution of the test compound, using conventional medicinal chemistry/animal model techniques.

30 As used herein, "limit" or "limiting" and "treat" or "treatment" are interchangeable terms. The terms include a postponement of development of bone deficit symptoms and/or a reduction in the severity of such symptoms that will or are expected to develop. The

terms further include ameliorating existing bone or cartilage deficit symptoms, preventing additional symptoms, ameliorating or preventing the underlying metabolic causes of symptoms, preventing or reversing bone resorption and/or encouraging bone growth. Thus, the terms denote that a beneficial result has been conferred on a vertebrate subject
5 with a cartilage, bone or skeletal deficit, or with the potential to develop such deficit.

By "bone deficit" is meant an imbalance in the ratio of bone formation to bone resorption, such that, if unmodified, the subject will exhibit less bone than desirable, or the subject's bones will be less intact and coherent than desired. Bone deficit may also result from fracture, from surgical intervention or from dental or periodontal disease. By
10 "cartilage defect" is meant damaged cartilage, less cartilage than desired, or cartilage that is less intact and coherent than desired.

Representative uses of the compounds of the present invention include: repair of bone defects and deficiencies, such as those occurring in closed, open and non-union fractures; prophylactic use in closed and open fracture reduction; promotion of bone
15 healing in plastic surgery; stimulation of bone ingrowth into non-cemented prosthetic joints and dental implants; elevation of peak bone mass in pre-menopausal women; treatment of growth deficiencies; treatment of periodontal disease and defects, and other tooth repair processes; increase in bone formation during distraction osteogenesis; and treatment of other skeletal disorders, such as age-related osteoporosis, post-menopausal osteoporosis,
20 glucocorticoid-induced osteoporosis or disuse osteoporosis and arthritis. The compounds of the present invention can also be useful in repair of congenital, trauma-induced or surgical resection of bone (for instance, for cancer treatment), and in cosmetic surgery. Further, the compounds of the present invention can be used for limiting or treating cartilage defects or disorders, and may be useful in wound healing or tissue repair.

25 Bone or cartilage deficit or defect can be treated in vertebrate subjects by administering compounds of the invention which exhibit certain structural and functional characteristics. The compositions of the invention may be administered systemically or locally. For systemic use, the compounds herein are formulated for parenteral (e.g., intravenous, subcutaneous, intramuscular, intraperitoneal, intranasal or transdermal) or
30 enteral (e.g., oral or rectal) delivery according to conventional methods. Intravenous administration can be by a series of injections or by continuous infusion over an extended period. Administration by injection or other routes of discretely spaced administration can

be performed at intervals ranging from weekly to once to three times daily. Alternatively, the compounds disclosed herein may be administered in a cyclical manner (administration of disclosed compound; followed by no administration; followed by administration of disclosed compound, and the like). Treatment will continue until the desired outcome is

5 achieved. In general, pharmaceutical formulations will include a compound of the present invention in combination with a pharmaceutically acceptable vehicle, such as saline, buffered saline, 5% dextrose in water, borate-buffered saline containing trace metals or the like. Formulations may further include one or more excipients, preservatives, solubilizers, buffering agents, albumin to prevent protein loss on vial surfaces, lubricants, fillers, stabilizers, etc. Methods of formulation are well known in the art and are disclosed, for example, in Remington's Pharmaceutical Sciences, Gennaro, ed., Mack Publishing Co., Easton PA, 1990, which is incorporated herein by reference. Pharmaceutical compositions for use within the present invention can be in the form of sterile, non-pyrogenic liquid solutions or suspensions, coated capsules, suppositories, lyophilized powders, transdermal patches or other forms known in the art. Local administration may be by injection at the site of injury or defect, or by insertion or attachment of a solid carrier at the site, or by direct, topical application of a viscous liquid, or the like. For local administration, the delivery vehicle preferably provides a matrix for the growing bone or cartilage, and more preferably is a vehicle that can be absorbed by the subject without adverse effects.

10 20 Delivery of compounds herein to wound sites may be enhanced by the use of controlled-release compositions, such as those described in pending U.S. Patent Application No. 07/871,246 (corresponding to WIPO publication WO 93/20859, which is incorporated herein by reference in its entirety). Films of this type are particularly useful as coatings for prosthetic devices and surgical implants. The films may, for example, be wrapped around the outer surfaces of surgical screws, rods, pins, plates and the like. Implantable devices of this type are routinely used in orthopedic surgery. The films can also be used to coat bone filling materials, such as hydroxyapatite blocks, demineralized bone matrix plugs, collagen matrices and the like. In general, a film or device as described herein is applied to the bone at the fracture site. Application is generally by implantation 15 25 30 into the bone or attachment to the surface using standard surgical procedures.

In addition to the copolymers and carriers noted above, the biodegradable films and matrices may include other active or inert components. Of particular interest are those

agents that promote tissue growth or infiltration, such as growth factors. Exemplary growth factors for this purpose include epidermal growth factor (EGF), fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), transforming growth factors (TGFs), parathyroid hormone (PTH), leukemia inhibitory factor (LIF), and insulin-like growth factors (IGFs) and the like. Agents that promote bone growth, such as bone morphogenetic proteins (U.S. Patent No. 4,761,471; PCT Publication WO 90/11366), osteogenin (Sampath *et al.* *Proc. Natl. Acad. Sci. USA* (1987) 84:7109-13) and NaF (Tencer *et al.* *J. Biomed. Mat. Res.* (1989) 23: 571-89) are also preferred. Biodegradable films or matrices include calcium sulfate, tricalcium phosphate, hydroxyapatite, polylactic acid, polyanhydrides, bone or dermal collagen, pure proteins, extracellular matrix components and the like and combinations thereof. Such biodegradable materials may be used in combination with non-biodegradable materials, to provide desired mechanical, cosmetic or tissue or matrix interface properties.

Alternative methods for delivery of compounds of the present invention include use of ALZET osmotic minipumps (Alza Corp., Palo Alto, CA); sustained release matrix materials such as those disclosed in Wang *et al.* (PCT Publication WO 90/11366); electrically charged dextran beads, as disclosed in Bao *et al.* (PCT Publication WO 92/03125); collagen-based delivery systems, for example, as disclosed in Ksander *et al.* *Ann. Surg.* (1990) 211(3):288-94; methylcellulose gel systems, as disclosed in Beck *et al.* *J. Bone Min. Res.* (1991) 6(11):1257-65; and alginate-based systems, as disclosed in Edelman *et al.* *Biomaterials* (1991) 12:619-26 and the like. Other methods well known in the art for sustained local delivery in bone include porous coated metal prostheses that can be impregnated and solid plastic rods with therapeutic compositions incorporated within them.

The compounds of the present invention may also be used in conjunction with agents that inhibit bone resorption. Antiresorptive agents, such as estrogen, bisphosphonates and calcitonin, are preferred for this purpose. More specifically, the compounds disclosed herein may be administered for a period of time (for instance, months to years) sufficient to obtain correction of a bone deficit condition. Once the bone deficit condition has been corrected, the vertebrate can be administered an anti-resorptive compound to maintain the corrected bone condition. Alternatively, the compounds disclosed herein may be administered with an anti-resorptive compound in a cyclical manner.

(administration of disclosed compound, followed by anti-resorptive, followed by disclosed compound, and the like).

In additional formulations, conventional preparations such as those described below may be used.

5 Aqueous suspensions may contain the active ingredient in admixture with pharmacologically acceptable excipients, comprising suspending agents, such as methyl cellulose; and wetting agents, such as lecithin, lysolecithin or long-chain fatty alcohols. The said aqueous suspensions may also contain preservatives, coloring agents, flavoring agents and sweetening agents in accordance with industry standards.

10 Preparations for topical and local application comprise aerosol sprays, lotions, gels and ointments in pharmaceutically appropriate vehicles which may comprise lower aliphatic alcohols, polyglycols such as glycerol, polyethylene glycol, esters of fatty acids, oils and fats, and silicones. The preparations may further comprise antioxidants, such as ascorbic acid or tocopherol, and preservatives, such as p-hydroxybenzoic acid esters.

15 Parenteral preparations comprise particularly sterile or sterilized products. Injectable compositions may be provided containing the active compound and any of the well known injectable carriers. These may contain salts for regulating the osmotic pressure.

If desired, the osteogenic agents can be incorporated into liposomes by any of the reported methods of preparing liposomes for use in treating various pathogenic conditions.

20 The present compositions may utilize the compounds noted above incorporated in liposomes in order to direct these compounds to macrophages, monocytes, other cells and tissues and organs which take up the liposomal composition. The liposome-incorporated compounds of the invention can be utilized by parenteral administration, to allow for the efficacious use of lower doses of the compounds. Ligands may also be incorporated to 25 further focus the specificity of the liposomes.

Suitable conventional methods of liposome preparation include, but are not limited to, those disclosed by Bangham, A.D. *et al. J Mol Biol* (1965) 23:238-252, Olson, F. *et al. Biochim Biophys Acta* (1979) 557:9-23, Szoka, F. *et al. Proc Natl Acad Sci USA* (1978) 75:4194-4198, Mayhew, E. *et al. _____* (1984) 775:169175, Kim, S. *et al. Biochim Biophys Acta* (1983) 728:339-348, and Mayer, *et al. Biochim Biophys Acta* (1986) 858:161-168.

The liposomes may be made from the present compounds in combination with any of the conventional synthetic or natural phospholipid liposome materials including phospholipids from natural sources such as egg, plant or animal sources such as phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, sphingomyelin, 5 phosphatidylserine, or phosphatidylinositol. Synthetic phospholipids that may also be used, include, but are not limited to: dimyristoylphosphatidylcholine, dioleoylphosphatidylcholine, dipalmitoylphosphatidylcholine and distearoylphosphatidylcholine, and the corresponding synthetic phosphatidylethanolamines and phosphatidylglycerols. Cholesterol or other sterols, cholesterol hemisuccinate, glycolipids, cerebrosides, fatty acids, gangliosides, 10 sphingolipids, 1,2-bis(oleoyloxy)-3-(trimethyl ammonio) propane (DOTAP), N-[1-(2,3-dioleoyl) propyl-N,N,N-trimethylammonium chloride (DOTMA), and other cationic lipids may be incorporated into the liposomes, as is known to those skilled in the art. The relative amounts of phospholipid and additives used in the liposomes may be varied if desired. The preferred ranges are from about 60 to 90 mole percent of the phospholipid; cholesterol, 15 cholesterol hemisuccinate, fatty acids or cationic lipids may be used in amounts ranging from 0 to 50 mole percent. The amounts of the present compounds incorporated into the lipid layer of liposomes can be varied with the concentration of the lipids ranging from about 0.01 to about 50 mole percent.

Using conventional methods, approximately 20 to 30% of the compound present in 20 solution can be entrapped in liposomes; thus, approximately 70 to 80% of the active compound is wasted. In contrast, where the compound is incorporated into liposomes, virtually all of the compound is incorporated into the liposome, and essentially none of the active compound is wasted.

The liposomes with the above formulations may be made still more specific for their 25 intended targets with the incorporation of monoclonal antibodies or other ligands specific for a target. For example, monoclonal antibodies to the BMP receptor may be incorporated into the liposome by linkage to phosphatidylethanolamine (PE) incorporated into the liposome by the method of Leserman, L. *et al. Nature* (1980) 288:602-604.

Veterinary uses of the disclosed compounds are also contemplated. Such uses 30 would include limitation or treatment of bone or cartilage deficits or defects in domestic animals, livestock and thoroughbred horses. The compounds described herein can also

modify a target tissue or organ environment, so as to attract bone-forming cells to an environment in need of such cells.

The compounds of the present invention may also be used to stimulate growth of bone-forming cells or their precursors, or to induce differentiation of bone-forming cell
5 precursors, either *in vitro* or *ex vivo*. As used herein, the term "precursor cell" refers to a cell that is committed to a differentiation pathway, but that generally does not express markers or function as a mature, fully differentiated cell. As used herein, the term "mesenchymal cells" or "mesenchymal stem cells" refers to pluripotent progenitor cells that are capable of dividing many times, and whose progeny will give rise to skeletal tissues,
10 including cartilage, bone, tendon, ligament, marrow stroma and connective tissue (see A. Caplan *J. Orthop. Res.* (1991) 9:641-50). As used herein, the term "osteogenic cells" includes osteoblasts and osteoblast precursor cells. More particularly, the disclosed compounds are useful for stimulating a cell population containing marrow mesenchymal cells, thereby increasing the number of osteogenic cells in that cell population. In a
15 preferred method, hematopoietic cells are removed from the cell population, either before or after stimulation with the disclosed compounds. Through practice of such methods, osteogenic cells may be expanded. The expanded osteogenic cells can be infused (or reinfused) into a vertebrate subject in need thereof. For instance, a subject's own mesenchymal stem cells can be exposed to compounds of the present invention *ex vivo*, and
20 the resultant osteogenic cells could be infused or directed to a desired site within the subject, where further proliferation and/or differentiation of the osteogenic cells can occur without immunorejection. Alternatively, the cell population exposed to the disclosed compounds may be immortalized human fetal osteoblastic or osteogenic cells. If such cells are infused or implanted in a vertebrate subject, it may be advantageous to
25 "immunoprotect" these non-self cells, or to immunosuppress (preferably locally) the recipient to enhance transplantation and bone or cartilage repair.

Within the present invention, an "effective amount" of a composition is that amount which produces a statistically significant effect. For example, an "effective amount" for therapeutic uses is the amount of the composition comprising an active compound herein
30 required to provide a clinically significant increase in healing rates in fracture repair; reversal of bone loss in osteoporosis; reversal of cartilage defects or disorders; prevention or delay of onset of osteoporosis; stimulation and/or augmentation of bone formation in

- fracture non-unions and distraction osteogenesis; increase and/or acceleration of bone growth into prosthetic devices; and repair of dental defects. Such effective amounts will be determined using routine optimization techniques and are dependent on the particular condition to be treated, the condition of the patient, the route of administration, the
- 5 formulation, and the judgment of the practitioner and other factors evident to those skilled in the art. The dosage required for the compounds of the invention (for example, in osteoporosis where an increase in bone formation is desired) is manifested as a statistically significant difference in bone mass between treatment and control groups. This difference in bone mass may be seen, for example, as a 5-20% or more increase in bone mass in the
- 10 treatment group. Other measurements of clinically significant increases in healing may include, for example, tests for breaking strength and tension, breaking strength and torsion, 4-point bending, increased connectivity in bone biopsies and other biomechanical tests well known to those skilled in the art. General guidance for treatment regimens is obtained from experiments carried out in animal models of the disease of interest.
- 15 The dosage of the compounds of the invention will vary according to the extent and severity of the need for treatment, the activity of the administered compound, the general health of the subject, and other considerations well known to the skilled artisan. Generally, they can be administered to a typical human on a daily basis on an oral dose of about 0.1 mg/kg-1000 mg/kg, and more preferably from about 1 mg/kg to about 200 mg/kg. The
- 20 parenteral dose will appropriately be 20-100% of the oral dose.

Screening Assays

- The osteogenic activity of the compounds used in the methods of the invention can be verified using *in vitro* screening techniques, such as the assessment of transcription of a reporter gene coupled to a bone morphogenetic protein-associated promoter, as described above, or in alternative assays such as the following:

Technique for Neonatal Mouse Calvaria Assay (*In vitro*)

- This assay is similar to that described by Gowen M. & Mundy G. *J Immunol* (1986) 30 136:2478-82. Briefly, four days after birth, the front and parietal bones of ICR Swiss white mouse pups are removed by microdissection and split along the sagittal suture. The bones are incubated in BGJb medium (Irvine Scientific, Santa Ana, CA) plus 0.02% (or lower

concentration) β -methylcyclodextrin, wherein the medium also contains test or control substances, at 37°C in a humidified atmosphere of 5% CO₂ and 95% air for 96 hours.

Following this, the bones are removed from the incubation media and fixed in 10% buffered formalin for 24-48 hours, decalcified in 14% EDTA for 1 week, processed

5 through graded alcohols; and embedded in paraffin wax. Three μm sections of the calvaria are prepared. Representative sections are selected for histomorphometric assessment of bone formation and bone resorption. Bone changes are measured on sections cut 200 μm apart. Osteoblasts and osteoclasts are identified by their distinctive morphology.

Other auxillary assays can be used as controls to determine non-BMP promoter-
10 mediated effects of test compounds. For example, mitogenic activity can be measured using screening assays featuring a serum-response element (SRE) as a promoter and a luciferase reporter gene. More specifically, these screening assays can detect signalling through SRE-mediated pathways, such as the protein kinase C pathway. For instance, an osteoblast activator SRE-luciferase screen and an insulin mimetic SRE-luciferase screen are
15 useful for this purpose. Similarly, test compound stimulation of cAMP response element (CRE)-mediated pathways can also be assayed. For instance, cells transfected with receptors for PTH and calcitonin (two bone-active agents) can be used in CRE-luciferase screens to detect elevated cAMP levels. Thus, the BMP promoter specificity of a test compound can be examined through use of these types of auxillary assays.

20

In vivo Assay of Effects of Compounds on Murine Calvarial Bone Growth

Male ICR Swiss white mice, aged 4-6 weeks and weighing 13-26 gm, are employed, using 4-5 mice per group. The calvarial bone growth assay is performed as described in PCT application WO 95/24211, incorporated by reference. Briefly, the test
25 compound or appropriate control vehicle is injected into the subcutaneous tissue over the right calvaria of normal mice. Typically, the control vehicle is the vehicle in which the compound was solubilized, and is PBS containing 5% DMSO or is PBS containing Tween (2 $\mu\text{l}/10 \text{ ml}$). The animals are sacrificed on day 14 and bone growth measured by histomorphometry. Bone samples for quantitation are cleaned from adjacent tissues and
30 fixed in 10% buffered formalin for 24-48 hours, decalcified in 14% EDTA for 1-3 weeks, processed through graded alcohols; and embedded in paraffin wax. Three to five μm

sections of the calvaria are prepared, and representative sections are selected for histomorphometric assessment of the effects on bone formation and bone resorption. Sections are measured by using a camera lucida attachment to trace directly the microscopic image onto a digitizing plate. Bone changes are measured on sections cut 200 µm apart, over 4 adjacent 1x1 mm fields on both the injected and noninjected sides of the calvaria. New bone is identified by its characteristic woven structure, and osteoclasts and osteoblasts are identified by their distinctive morphology. Histomorphometry software (OsteoMeasure, Osteometrics, Inc., Atlanta) is used to process digitizer input to determine cell counts and measure areas or perimeters.

10

Additional *In Vivo* Assays

Lead compounds can be further tested in intact animals using an *in vivo*, dosing assay. Prototypical dosing may be accomplished by subcutaneous, intraperitoneal or oral administration, and may be performed by injection, sustained release or other delivery techniques. The time period for administration of test compound may vary (for instance, 28 days as well as 35 days may be appropriate). An exemplary, *in vivo* subcutaneous dosing assay may be conducted as follows:

In a typical study, 70 three-month-old female Sprague-Dawley rats are weight-matched and divided into seven groups, with ten animals in each group. This includes a baseline control group of animals sacrificed at the initiation of the study; a control group administered vehicle only; a PBS-treated control group; and a positive control group administered a compound (non-protein or protein) known to promote bone growth. Three dosage levels of the compound to be tested are administered to the remaining three groups.

Briefly, test compound, positive control compound, PBS, or vehicle alone is administered subcutaneously once per day for 35 days. All animals are injected with calcein nine days and two days before sacrifice (two injections of calcein administered each designated day). Weekly body weights are determined. At the end of the 35-day cycle, the animals are weighed and bled by orbital or cardiac puncture. Serum calcium, phosphate, osteocalcin, and CBCs are determined. Both leg bones (femur and tibia) and lumbar vertebrae are removed, cleaned of adhering soft tissue, and stored in 70% ethanol for evaluation, as performed by peripheral quantitative computed tomography (pQCT; Ferretti,

J. Bone (1995) 17:353S-64S), dual energy X-ray absorptiometry (DEXA; Laval-Jeantet A. et al. *Calcif Tissue Intl* (1995) 56:14-18; J. Casez et al. *Bone and Mineral* (1994) 26:61-68) and/or histomorphometry. The effect of test compounds on bone remodeling can thus be evaluated.

5 Lead compounds can also be tested in acute ovariectomized animals (prevention model) using an *in vivo* dosing assay. Such assays may also include an estrogen-treated group as a control. An exemplary subcutaneous dosing assay is performed as follows:

In a typical study, 80 three-month-old female Sprague-Dawley rats are weight-matched and divided into eight groups, with ten animals in each group. This includes a baseline control group of animals sacrificed at the initiation of the study; three control groups (sham ovariectomized (sham OVX) + vehicle only; ovariectomized (OVX) + vehicle only; PBS-treated OVX); and a control OVX group that is administered a compound known to promote bone growth. Three dosage levels of the compound to be tested are administered to the remaining three groups of OVX animals.

15 Since ovariectomy (OVX) induces hyperphagia, all OVX animals are pair-fed with sham OVX animals throughout the 35 day study. Briefly, test compound, positive control compound, PBS, or vehicle alone is administered subcutaneously once per day for 35 days. Alternatively, test compound can be formulated in implantable pellets that are implanted for 35 days, or may be administered orally, such as by gastric gavage. All animals, including
20 sham OVX/vehicle and OVX/vehicle groups, are injected intraperitoneally with calcein nine days and two days before sacrifice (two injections of calcein administered each designated day, to ensure proper labeling of newly formed bone). Weekly body weights are determined. At the end of the 35-day cycle, the animals' blood and tissues are processed as described above.

25 Lead compounds may also be tested in chronic OVX animals (treatment model). An exemplary protocol for treatment of established bone loss in ovariectomized animals that can be used to assess efficacy of anabolic agents may be performed as follows. Briefly, 80 to 100 six month old female, Sprague-Dawley rats are subjected to sham surgery (sham OVX) or ovariectomy (OVX) at time 0, and 10 rats are sacrificed to serve as baseline
30 controls. Body weights are recorded weekly during the experiment. After approximately 6 weeks of bone depletion (42 days), 10 sham OVX and 10 OVX rats are randomly selected for sacrifice as depletion period controls. Of the remaining animals, 10 sham OVX and 10

- OVX rats are used as placebo-treated controls. The remaining OVX animals are treated with 3 to 5 doses of test drug for a period of 5 weeks (35 days). As a positive control, a group of OVX rats can be treated with an agent such as PTH, a known anabolic agent in this model (Kimmel *et al. Endocrinology* (1993) 132:1577-84). To determine effects on bone formation, the following procedure can be followed. The femurs, tibiae and lumbar vertebrae 1 to 4 are excised and collected. The proximal left and right tibiae are used for pQCT measurements, cancellous bone mineral density (BMD) (gravimetric determination), and histology, while the midshaft of each tibiae is subjected to cortical BMD or histology. The femurs are prepared for pQCT scanning of the midshaft prior to biomechanical testing.
- 5 With respect to lumbar vertebrae (LV), LV2 are processed for BMD (pQCT may also be performed); LV3 are prepared for undecalcified bone histology; and LV4 are processed for mechanical testing.
- 10

Nature of the Compounds Useful in the Invention

15 All of the compounds of the invention contain two aromatic systems, Ar¹ and Ar², spaced apart by a linker at a distance of 1.5-15Å, and may contain at least one nitrogen atom. Both the systems represented by Ar¹ and Ar² may contain non-interfering substituents. The non-interfering substituents on the aromatic system represented by Ar¹ and the non-interfering substituents on the aromatic system represented by Ar² are represented in the formulae herein by R^a and R^b, respectively; however, it is recognized that the designation of one Ar as Ar¹ and the other as Ar² is arbitrary. For ease of reference, each is designated separately; it will, however, be evident that the linkers described below, unless palindromic, could thus exist in the compounds in "reverse" order of atoms. Generally, the non-interfering substituents can be of wide variety. Among substituents that do not interfere with the beneficial effect of the compounds of the invention on bone in treated subjects are included alkyl (1-6C, preferably lower alkyl 1-4C), including straight or branched-chain forms thereof, alkenyl (1-6C, preferably 1-4C), alkynyl (1-6C, preferably 1-4C), all of which can be straight or branched chains and may contain further substituents; halogens, including F, Cl, Br and I; siloxy, OR, SR, NR₂, OOCR, COOR, NCOR,

20

25

30

aromatic system, they may form a ring. Further, rings may be included in substituents which contain sufficient carbon atoms and heteroatoms to provide this possibility.

Preferred non-interfering substituents include hydrocarbyl groups of 1-6C, including saturated and unsaturated, linear or branched hydrocarbyl as well as hydrocarbyl groups

- 5 containing ring systems; halo groups, alkoxy, hydroxy, amino, monoalkyl- and dialkylamino where the alkyl groups are 1-6C, CN, CF₃, and COOR.

Although the number of R^a and R^b substituents may typically be 0-4 or 0-5 depending on the available positions in the aromatic system, preferred embodiments include those wherein the number of R^a is 0, 1 or 2 and of R^b is 0, 1 or 2.

- 10 The linker group, L, may be a covalent bond or any group having a valence of at least two and covering a linear distance of from about 1.5 to about 15 Angstroms, including those that contain cyclic moieties, that meet this spatial requirement. Useful linkers are divided, by definition herein, into three general categories: (1) flexible non-conjugating linkers, (2) flexible conjugating linkers, and (3) constrained linkers. The
15 preferred choice of linker will depend on the choices for Ar¹ and Ar². Not all of the linkers defined below are suitable for all Ar¹ and Ar² combinations.


As defined herein, *flexible non-conjugating* linkers are those that link only one position of Ar¹ to one position of Ar², and provide only a single covalent bond or a single chain between Ar¹ and Ar². The chain may contain branches, but may not contain π-bonds

- 20 (except in the branches) or cyclic portions in the chain. The linker atoms in the chain itself rotate freely around single covalent bonds, and thus the linker has more than two degrees of freedom. Particularly useful flexible non-conjugating linkers, besides a covalent bond, are those of the formulae: -NR-, -CR₂-, -S-, or -O-, wherein R is H or alkyl (1-6C), more preferably H or lower alkyl (1-4C) and more preferably H. Also preferred are those of the
25 formulae: -NRCO-, -CONR-, -CR₂S-, -SCR₂-, -OCR₂-, -CR₂O-, -NRNR-, -CR₂CR₂-, -NRSO₂-, -SO₂NR-, -CR₂CO-, -COCR₂-, and -NR-NR-CO-CR₂- and its complement -CR₂-CO-NR-NR-, including the isosteres thereof. Also preferred are those of the formulae: -NR(CR₂)₂NR-, -O(CR₂)₂O-, and -S(CR₂)₂S-, including the isosteres thereof. The optimum choice of linker within this group is dependent on the nature of Ar¹ and Ar².

- 30 *Flexible conjugating* linkers are those that link only one position of Ar¹ to one position of Ar², but incorporate at least one double or triple bond and/or one or more cyclic systems and thus have only two degrees of freedom. A flexible conjugating linker may

form a completely conjugated π -bond linking system between Ar^1 and Ar^2 , thus providing for co-planarity of Ar^1 and Ar^2 . Examples of useful flexible conjugating linkers include: - $\text{RC}=\text{CR}-$; - $\text{N}=\text{N}-$; - $\text{C}=\text{C}-$; - $\text{RC}=\text{N}-$; - $\text{N}=\text{CR}-$; - $\text{NR}-\text{N}=\text{CR}-$; - $\text{NR}-\text{NR}-\text{CO}-\text{CR}=\text{CR}-$; and the like, where R is H or alkyl (1-6C); preferably H or lower alkyl (1-4C); and more preferably H.


Constrained linkers are those that have more than one point of attachment to either or both Ar^1 and Ar^2 and, thus, generally allow for only one degree of freedom. Constrained linkers most frequently form fused 5- or 6-membered cyclic moieties with Ar^1 and/or Ar^2 where either Ar^1 or Ar^2 has at least one substituent appropriately positioned to form a second covalent bond with the linker, e.g., where Ar^2 is a phenyl group with a reactive, ortho-positioned substituent, or is derivatized to the linker directly at the ortho position. (Although the aromatic moieties should properly be referred to as phenylene or naphthylene in such cases, generally the term "phenyl" or "naphthyl" is used herein to include both monovalent and bivalent forms of these moieties.) Examples of particularly useful constrained linkers include



and the like, where X is O, N, S or CR, and Y is CR₂ or C=O.

Many of the compounds useful in the invention are commercially available and can be synthesized by art-known methods. Those compounds useful in the invention which are new compounds, can similarly be obtained by methods generally known in the art.

In one set of compounds of the inventions, Ar¹ is a substituted or unsubstituted aromatic system containing a six-membered heterocycle and the compounds useful in the invention have the formula:



5

wherein R^a is a non-interfering substituent;

m is an integer of 0-4;

each dotted line represents an optional π-bond;

each Z is independently N, NR, O, S, CR or CR₂, where each R is independently H or alkyl (1-6C);


10

X is O, S, SO or SO₂;

L is a flexible linker; and

Ar² is a substituted or unsubstituted 6-membered aromatic ring.

A particularly preferred set of embodiments is of the formula:



15

in which:

R¹ is taken from the group: N=NAr, NR⁶COAr, CONR⁶Ar, CH₂OAr, CH₂NR⁶Ar, where Ar is a six-membered (un)substituted aromatic ring. Allowable substituents on this aromatic ring include:

20

halogen, straight or branched chain lower alkyl, alkenyl, or alkynyl, optionally substituted by a six-membered aromatic, cyclic alkyl, or cyclic alkenyl ring, hydroxyl, siloxy, acyloxy, straight or branched chain lower alkoxy, benzoyl, carboalkoxy, carbamoyl optionally substituted at nitrogen by lower chain alkyl or phenyl, or carboxy, in which

R^6 is taken from the group: hydrogen, or straight or branched chain lower alkyl;

R^2 and R^5 are individually taken from the group: H, hydroxy, siloxy, acyloxy, halo, cyano, straight or branched chain lower alkyl, or straight or branched chain lower alkoxy;

R^3 and R^4 are individually taken from the group: H, halogen, straight or branched chain lower alkyl, alkenyl, or alkynyl optionally substituted by a six-membered aromatic, cyclic alkyl, or cyclic alkenyl ring, hydroxyl, siloxy, acyloxy, straight or branched chain lower alkoxy, benzoyl, carboalkoxy, carbamoyl optionally substituted at nitrogen by lower chain alkyl or phenyl, and carboxy;

X and Y are either: NR⁸ and N, respectively, in which case X and Y are singly bonded, or CR⁹ and CR¹⁰, respectively, in which case X and Y are doubly bonded, wherein


R^8 is either H or lower alkyl;

R^9 and R^{10} are individually taken from the group: H, halo, and lower alkyl;

Z is taken from the group: O, S, SO, and SO₂, or salts thereof.


Compounds of the general structure I above can be prepared in a variety of ways, for example:

a) treating thiohydrazides of general structure II, or the corresponding thiohydrazone, in hot acetic acid in air,




25

b) reacting compounds of the general structure III with bromine,




c) heating compounds of general structure IV in a protic solvent.



5

: or


d) reacting compounds of the general structures V or VI with sodium hydride.



10


10

e) reacting compounds of the general structure VII with a base




; or

f) reacting pyrylium compounds of general structure VII with an appropriate nucleophile,



5 where R^2 , R^3 , R^4 , R^5 , are as defined above and R is taken from the group: Ar, NHAr, NHNHAr, COAr, carboalkoxy, alkoxy, NR^6COAr , CH_2OAr , and CH_2NR^6Ar , in which Ar and R^6 are as described above, followed, optionally, by conversion of any one or more of the groups, R, R^2 , R^3 , R^4 , R^5 into new groups R , R^2 , R^3 , R^4 , R^5 by deprotection, coupling, addition, substitution, or elimination; or by oxidation of the sulfur to sulfoxide or sulfone; and, if desired, by converting a compound of the general structure I into its salt or setting it free from its salt.

10 Example:
Diphenyl thiohydrazone is heated in refluxing acetic acid in air for 30 to 90 minutes to afford benzothiadiazene 1.



15


Specific representatives of compounds of the general structure I include:

3-phenylazo-1H-4,1,2-benzothiadizine

2-phenylazo-2H-benzopyran


20

Another group of compounds suitable for use in the methods of the invention are compounds of the formula:



wherein R^a is a non-interfering substituent;
 n is an integer of 0 and 5;
 5 L is a flexible linker which does not contain nitrogen; and
 Ar^2 is a substituted or unsubstituted phenyl or a substituted or unsubstituted naphthyl.

Particularly preferred embodiments of this group of compounds are those of the formula:



10

in which


R^{35} is taken from the group: H, hydroxy, alkoxy, acyloxy, and silyloxy;

15 R^{36} is either Ar, or COAr, in which Ar is (un)substituted phenyl in which the allowed substituents are taken from the group: H, hydroxy, (un)substituted alkoxy, acyloxy, siloxy, (un)substituted alkyl, (un)substituted alkenyl, or (un)substituted alkynyl, carboxy, carboalkoxy, carbamoyl optionally substituted at nitrogen by lower chain alkyl, and aryl;


R^{37} is taken from the group: H, hydroxy, alkoxy, halo, acyloxy, and siloxyl;

20 R^{38} is taken from the group: H, hydroxy, alkoxy, acyloxy, siloxy, (un)substituted alkoxy, acyloxy, siloxy, (un)substituted alkyl, (un)substituted alkenyl, and (un)substituted alkynyl, or salts thereof.


Compounds of general structure XXXV can be prepared by treating an acetophenone of general structure XXXVI with an appropriate aldehyde of general structure XXXVII under either basic or acidic conditions,




- 5 or by treating an appropriate alkyne of general structure XXXVIII with an acid halide of general structure XXXIX in the presence of a suitable catalyst, such as aluminum trichloride,



- 10 or by treating acid halides of the general structure XXXIX with (E)-1,2-bis(tri-n-butylstanyl)ethylene, or with a vinylstanane of general structure XL in the presence of a suitable catalyst, for example, a palladium catalyst.



or by treating an acetophenone of general structure XLI with a strong base,



- where R^{35} , R^{36} , R^{37} , and R^{38} are as defined above, followed, optionally, by conversion of any one or more of the groups R^{35} , R^{36} , R^{37} , and R^{38} into new groups R^{35} , R^{36} , R^{37} , and R^{38} by deprotection, coupling, addition, substitution, or elimination, and, if 5 desired, by converting a compound of the general structure XXXV into its salt or setting it free from its salt.

Specific representative compounds of general structure XXXV include:

- 10 2,4-dimethoxy-2'-hydroxychalcone
 1-(2-hydroxyphenyl)-3-(4-methoxyphenyl)propan-
 1,3-dione
 1,4-dioxo-1,4-diphenylbut-2-ene


Still another group of compounds useful in the invention are those of the formula:

15



- wherein R^a is a non-interfering substituent;
 n is an integer of 0 and 5;
 L is a constrained linker; and
 20 Ar^2 is a substituted or unsubstituted phenyl or a substituted or unsubstituted naphthyl.

Particularly preferred compounds in this group are those of formulas IX, XIV, and XX as follows:



in which:

R^{11} and R^{12} are individually taken from the group:

H, hydroxy, C₁₋₆ alkoxy, acetoxy, and C₁₋₁₂ (un)substituted alkyl;

5 R^{13} , R^{14} and R^{17} are individually taken from the group:

H, hydroxy, C₁₋₆ straight or branched chain alkoxy, and acetoxy;

R^{15} is taken from the group: Hydroxy, (un)substituted C₁₋₁₂ alkoxy, C₁₋₁₂ alkyl, (un)substituted alkenyl, and acetoxy;

10 R^{16} is taken from the group: H, hydroxy, (un)substituted lower alkoxy, acetoxy, (un)substituted alkyl, and (un)substituted alkenyl;
where R^{11} , R^{12} may form a 5-7 member (un)substituted carbocycle or heterocycle;
where R^{15} , R^{16} may form a 5-7 member (un)substituted carbocyclic or heterocyclic ring;

15 X^1 is either carbonyl or CH₂;

and the dotted line may be a double bond,

in which permissible substituents on the above mentioned substituted groups include: Lower alkyl, lower alkoxy, hydroxy, siloxy, halo, carboxyl, and aryl, with the following provisions:

if X^1 is carbonyl and

20 if R^{15} is hydroxy and if only one of R^{11} , R^{12} , or R^{13} is hydroxy, then at least one of R^{14} , R^{16} , and R^{17} must be other than H;

or if R^{15} is alkoxy, and if R^{11} , R^{12} , R^{13} together are H, then R^{17} can be neither H nor hydroxy;

25 or if R^{15} is (un)substituted alkoxy, and if R^{11} , R^{12} , and R^{13} together consist of only H, or H and one or two alkoxy, and R^{17} is H, then R^{14} must be other than H, Me or hydroxymethyl;


or if R¹⁵ is hydroxy or alkoxy, and if R¹¹, R¹², R¹³ together consist of only H, or H and one or two alkoxy, or H and only one or two alkyl, and R¹⁷ is C₁₋₄ alkyl, then at least one of R¹⁴ and R¹⁶ must be other than H;

5 or if R¹⁵ is hydroxy and if R¹¹, R¹², R¹³, R¹⁴, and R¹⁶ all are H, R¹⁷ must be neither H nor hydroxy;

or if R¹⁵ is iso-propoxy, and if R¹¹, R¹², and R¹³ together consist of only H, or H and one or two hydroxys, then at least one of R¹⁴, R¹⁶, R¹⁷ must be other than H;

10 or if R¹⁵ is 1,5 di(lower) alkyl C₅₋₁₀ alkyl, then at least one of R¹¹, R¹², R¹³, R¹⁴, R¹⁶, and R¹⁷ must be other than H;
or salts thereof.

Compounds of the general structure shown above can be made by a process wherein ketones of the structure (X) shown below:



15


are reacted with an alkylorthoformate in the presence of
a base, or

20 are reacted with an ethyloxalyl chloride in the presence
of pyridine, followed by hydrolysis and decarboxylation, or
are reacted with an alkyl formate in the presence of an
alkali metal, or


are reacted with an N,N-dialkyl formamide in the presence
of phosphorous oxychloride, or

25 are reacted with a cyanide in the presence of hydrogen
halide,


or by dehydrating 2-hydroxyisoflavanoids of the general structure (XI):



5 or by subjecting compounds of the general structure XII
to catalytic hydrogenation,



10 or by treating compounds of the general structure XIII,
available from alkylation of the corresponding phenylacetate with an appropriate benzylhalide, followed by reduction, with $(\text{PF}_6)_2\text{Rh}(\text{EtC}_5\text{Me}_4)(\text{C}_6\text{H}_6)$,




in which the groups R¹¹, R¹², R¹³, R¹⁴, R¹⁵, R¹⁶, and R¹⁷ are as defined above,
15 followed, optionally, by the conversion of any one or more of groups R¹¹, R¹², R¹³, R¹⁴,
R¹⁵, R¹⁶, and R¹⁷ into new groups R¹¹, R¹², R¹³, R¹⁴, R¹⁵, R¹⁶, and R¹⁷ by deprotection,

dehydrogenation, addition, substitution, or elimination, and, if desired, by converting a compound of the general structure IX into its salt or setting it free from its salt.

Example:


5 1,3,5-trihydroxybenzene is allowed to react with iso-pentynyl chloride, followed by catalytic hydrogenation, to give product 2. The compound 2 is allowed to react with the acid chloride 3 to provide the ketone 4. Ketone 4 is treated with ethyloxalyl chloride in pyridine at 0°C to afford an ester, which is hydrolyzed in aqueous acetone containing sodium carbonate to give the acid 5. When heated in refluxing toluene, acid 5 undergoes
10 decarboxylation to give compound 6, which upon treatment with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone gives the isoflavanoid 7.



Specific representatives of compounds of the general structure IX include:

- 25 tectorigenin
robustone
robustone methyl ether
7,2',4'-trihydroxyisoflavone
6,2',3'-trihydroxy-7,4'-dimethoxyisoflavan
30 8,4'-dimethoxy-7-hydroxisoflavone

Compounds of XIV have the structure:



in which:

5 R^{18} and R^{19} are individually taken from the group:

H, hydroxy, (un)substituted alkyl, (un)substituted alkoxy, COR^{21} carboxy, carboalkoxy, OR^{22} , carbamoyl optionally substituted at the nitrogen by lower chain alkyl or phenyl, acyloxy, halo, cyano, and azido.

10 R^{20} is taken from the group: H, hydroxy, halo, lower chain alkyl, acyloxy, and siloxy;


in which R^{21} is taken from the group: Alkyl, alkenyl,

alkynyl, aralkyl, (un)substituted phenyl, (un)substituted naphthyl, thienyl, furanyl, and pyridyl;


and R^{22} is comprised of a C₃₋₆ carbohydrate moiety;

15 or salts thereof.

Compounds of general structure XIV can be prepared by reacting ylides of general structure XV with either acid chlorides of general structure XVI or acid anhydrides of general structure XVII:




or by treating acids of the general structure XVIII with polyphosphoric acid, trifluoracetic anhydride, or similar reagent,



5

or by treating chalcones of general structure XIX with either base, or with base followed by treatment with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone.



10 in which the groups R^{18} , R^{19} , R^{20} are as above, followed, optionally, by conversion of any one or more of the groups R^{18} , R^{19} , R^{20} into new groups R'^{18} , R'^{19} , R'^{20} by deprotection, coupling, addition, substitution, or elimination, and, if desired, by converting a compound of general structure XIV into its salt or setting it free from its salt.

15

Specific representatives of compounds of the general structure XIV are:


5,4'-dimethyl-7-acetylflavone

7-benzoyloxyflavanone

apiin acetate

20

Compounds of structure XX are of the formula:



where

R^{23} , R^{24} , R^{25} , R^{26} are individually taken from the group:

5 H, hydroxy, (un)substituted alkoxy, siloxy, (un)substituted alkyl, (un)substituted alkenyl, halo, carboxyl, and acyloxy, and where R^{23} and R^{24} , and likewise R^{25} and R^{26} , can together equal a 5-7 member (un)substituted carbocyclic or heterocyclic ring, and where substituents on the above mentioned optionally substituted groups may include lower chain alkyl, lower chain alkoxy, hydroxy, 10 siloxy, acyloxy, halo, benzoyl, carboxy, carboalkoxy, and carbamoyl optionally substituted at nitrogen with lower chain alkyl, phenyl, thienyl, furyl, or pyridinyl;

Y^1 is taken from the group: O, $-OCH_2CH_2O-$, $-OCH_2CH_2S-$, $-OCH_2CH_2CH_2O-$, $-SCH_2CH_2CH_2S-$, and $-SCH_2CH_2S-$;

X^2 is taken from the group: CH₂, O, and S;


15

with the following provisions:


if X and Y are O and R^{24} or R^{25} are either both alkoxy, or alkoxy and alkyl, irrespective of order, then at least one of R^{23} and R^{26} must be other than H, or salts thereof.

20

Compounds of the general structure XX can be prepared by reacting amides of general structure XXI with *sec*-butyl lithium and tetramethylethylenediamine in THF, followed by addition of benzaldehydes of general structure XXII, and the addition of acid. The resulting lactones of general structure XXIII can be reduced by catalytic hydrogenation 25 or treatment with activated zinc in acid, followed by dehydration with trifluoracetic anhydride.



or, by treating diaryl ethers of general structure XXIV with sulfuric acid, aluminum trichloride, trifluoracetic anhydride, or similar reagent,



5


where R²³, R²⁴, R²⁵, R²⁶ are as defined above, followed, optionally, by conversion of any one or more of the groups R²³, R²⁴, R²⁵, R²⁶ into new groups R²³, R²⁴, R²⁵, R²⁶ by deprotection, coupling, addition, substitution, or elimination, and, if desired, by converting a compound of the general structure XX into its salt or setting it free from its salt.

10

Specific representatives of compounds of the general structure XX include:

3-isopropoxyanthrone

Another group that is useful in the invention are of the formula:



in which:

X^3 is NR^{27} , X^4 is CR^{30} , X^5 is O, X^6 is CR^{31} , X^7 is O^- ;

- 5 or X^3 is NR^{30} , X^4 is CR^{27} or N, X^5 is NR^{31} , X^6 is CR^{28} , X^7 is O^- or S^- ;
- or X^3 is NR^{27} , X^4 is CR^{30} , X^5 is NR^{28} , X^6 is CR^{31} , X^7 is O^- or S^- ;
- or X^3 is NR^{27} , X^4 is CR^{28} or N, X^5 is NR^{30} , X^6 is CR^{29} , X^7 is NR^{32} ;
- or X^3 is NR^{30} , X^4 is CR^{27} or N, X^5 is NR^{28} , X^6 is CR^{29} , X^7 is NR^{32} ;
- or X^3 is NR^{27} , X^4 is CR^{30} , X^5 is S, X^6 is CR^{31} , X^7 is NR^{32} ;
- 10 or X^3 is NR^{30} , X^4 is CR^{27} , X^5 is S, X^6 is CR^{28} , X^7 is NR^{32} ;
- or X^3 is S, X^4 is CR^{30} , X^5 is NR^{27} , X^6 is CR^{31} , X^7 is O^- or S^- ;
- or X^3 is S, X^4 is CR^{30} , X^5 is NR^{27} , X^6 is CR^{28} , X^7 is NR^{32} ;
- or X^3 is S, X^4 is CR^{27} , X^5 is NR^{30} , X^6 is CR^{28} , X^7 is NR^{32} ;
- or X^3 is S, X^4 is CR^{30} , X^5 is S, X^6 is CR^{27} , X^7 is NR^{32} ;
- 15 or X^3 is S, X^4 is CR^{30} , X^5 is S, X^6 is CR^{31} , X^7 is O^- ;
- or X^3 is NR^{30} , X^4 is CR^{27} or N, X^5 is NR^{31} , X^6 is N, X^7 is O^- or S^- ;
- or X^3 is NR^{27} , X^4 is CR^{30} , X^5 is NR^{28} , X^6 is N, X^7 is NR^{32} or CZ^2Z^3 ;
- or X^3 is NR^{27} , X^4 is CR^{28} or N, X^5 is NR^{30} , X^6 is N, X^7 is NR^{32} or CZ^2Z^3 ;
- 20 or X^3 is NR^{30} , X^4 is N, X^5 is S, X^6 is CR^{31} , X^7 is O^- ;
- or X^3 is S, X^4 is CR^{27} , X^5 is NR^{30} , X^6 is N, X^7 is NR^{32} ;
- or X^3 is S, X^4 is CR^{30} , X^5 is NR^{27} , X^6 is N, X^7 is NR^{32} ;
- or X^3 is O or S, X^4 is N, X^5 is NR^{30} , X^6 is N, X^7 is NR^{32} ;

in which

25 R^{27} , R^{28} and R^{29} are individually straight or branched chain

lower alkyl;

R^{30} and R^{31} are individually taken from the group:

hydrogen, straight or branched chain (un)substituted alkyl, (un)substituted aromatic, in which the substituents may include: Halogen, straight or branched chain lower alkyl, alkenyl, alkynyl optionally substituted by a six-membered aromatic, cyclic alkyl, or cyclic alkenyl ring, hydroxyl, straight or branched chain alkoxy, benzoyl, carboalkoxy, carbamoyl optionally substituted at nitrogen by lower chain alkyl or phenyl, or carboxy;

5 R³² is taken from the group:

Ar, COAr, COR³³, where Ar is a six-membered (un)substituted aromatic ring, in which substituents on this ring may include: Halogen, straight or branched chain lower alkyl, alkenyl, alkynyl optionally substituted by a six-membered aromatic, cyclic alkyl, or cyclic alkenyl ring, hydroxyl, straight or branched chain alkoxy, benzoyl, carboalkoxy, carbamoyl optionally substituted at nitrogen by lower chain alkyl or phenyl, or carboxy;

10 R³³ is taken from the group: Hydrogen, and straight or

15 branched chain alkyl;


Z² and Z³ are individually taken from the group: CN and
CO₂R³⁴;

R³⁴ is taken from the group: Hydrogen, straight or
20 branched chain alkyl, and (un)substituted aromatic;


or salts thereof.

Compounds of general structure XXV above can be prepared by treating
compounds of general structure XXVI, where X⁸ is NR³⁰ or S, X⁹ is CR³⁰ or N, X¹⁰ is
NR³⁰ or S, Z⁴ is CO₂H, CO₂R³⁰ or CN, with acid chlorides or anhydrides,


25




or by reacting compounds of general structure XXVII, where X^{11} is NR^{30} or S, X^{12} is N or CR³⁰, X^{13} is halogen, SMe, or OEt, with amines, sulfides or enolates,



5 or by reacting compounds of general structure XXVIII, where X^{15} is O or S with isocyanates, isothiocyanates, or carbon disulfide.




or by reacting compounds of general structure XXIX with sodium hydroxide,




10

or by reacting compounds of general structure XXX with alkyl tosylates, aryl tosylates or alkyl halides.



xxx


or by reacting compounds of general structure XXXI with aryl isocyanide dichlorides, phosgene, thiophosgogene, or 3,3-bis(methylthio)acrylonitriles,



XXXI


5

or by reacting compounds of general structure XXXII, where X¹⁶ is O, S, or NH, with sodium ethoxide or HCl in the presence of acid chlorides or HCl in the presence of acid anhydrides.




10

or by reacting compounds of general structure XXXIII, where X^{17} is NH or S, with acid chlorides, acid anhydrides, or HONO.



or by reacting compounds of general structure XXXIV with Cu(acac)₂,



5 where R²², R²⁸, R²⁹, R³⁰, R³¹, R³², R³³, and R³⁴ are as defined above, followed, optionally, by conversion of any one or more of the groups R²², R²⁸, R²⁹, R³⁰, R³¹, R³², R³³, and R³⁴ into new groups R²², R²⁸, R²⁹, R³⁰, R³¹, R³², R³³, and R³⁴ by deprotection, coupling, addition, substitution, or elimination, and, if desired, by converting a compound of the general structure XXV into its salt or setting it free from its salt.

10 Specific representatives of compounds of the general structure XXV include:

3-(4-chlorophenyl)-1,2,3,4-oxatriazolium-5-(4-chlorophenyl)aminide
1,3-di(4-methylphenyl)-1,2,3,4-tetrazolium-5-oxide.

The following examples are intended to illustrate, but not to limit, the invention.

15

Example 1


Compound 59-0008 was synthesized according to the procedure of McDonald, W. S., *et al. Chem Comm* (1969) 392-393; Irving, H. N. N. H. *et al. Anal Chim Acta* (1970) 49:261-266. Briefly, 10.0 g of dithizone was taken up in 100 ml EtOH and 50 ml AcOH and heated at reflux for 18 h. After cooling, this was diluted first with 100 ml water and then with 50 ml 1N NaOH. This was then further neutralized by the addition of 6 N NaOH to bring the pH to 5.0. This deep purple mixture was then concentrated on a rotavapor to remove organics. Once the liquid had lost all of its purple color, this was filtered to collect the dark precipitate. Purification by flash chromatography (4.5 x 25.7 cm; EtAc/Hep. (1:4); Rf 0.22) followed by recrystallization from EtOH gave 2.15 g (25% yield) of dark

purple crystals, mp=184-185 °C. ^1H NMR (CDCl_3) 7.90 (d of d, $J_1=7.7$, $J_2=2.2$, 2H), 7.64 (hump, 1H), 7.49 (m, 3H), 7.02 (m, 1H), 6.91 (m, 2H), 6.55 (d, $J=8.1$, 1H). MS (EI) 254 (47, M+), 105 (26), 77 [100], 51 (27). HRMS (EI, M+) 254.0626 (calcd 254.0626182). Anal. Calcd for $\text{C}_{13}\text{H}_{10}\text{N}_4\text{S}$: C, 61.40; H, 3.96; N, 22.03. Found: C, 5 61.40; H, 4.20; N, 22.06.

Example 2

High Throughput Screening

Several thousand compounds were tested in the assay system set forth in U.S. Serial 10 No. 08/458,434, filed 2 June 1995, and incorporated herein by reference. The standard positive control was a compound of the invention, 59-0008 (also denoted "OS8"), which is of the formula:



In more detail, the 2T3-BMP-2-LUC cells, a stably transformed osteoblast cell line 15 described in Ghosh-Choudhury *et al. Endocrinology* (1996) 137:331-39, referenced above, was employed. The cells were cultured using α -MEM, 10% FCS with 1% penicillin/streptomycin and 1% glutamine ("plating medium"), and were split 1:5 once per week. For the assay, the cells were resuspended in a plating medium containing 4% FCS, plated in microtiter plates at a concentration of 5×10^3 cells (in 50 μl)/well, and incubated 20 for 24 hours at 37°C in 5% CO₂. To initiate the assay, 50 μl of the test compound or the control in DMSO was added at 2X concentration to each well, so that the final volume was 100 μl . The final serum concentration was 2% FCS, and the final DMSO concentration was 1%. Compound 59-0008 (10 μM) was used as a positive control.

The treated cells were incubated for 24 hours at 37°C and 5% CO₂. The medium 25 was then removed, and the cells were rinsed three times with PBS. After removal of excess PBS, 25 μl of 1X cell culture lysing reagent (Promega #E153A) was added to each well and incubated for at least ten minutes. Optionally, the plates/samples could be frozen at

this point. To each well was added 50 μ l of luciferase substrate (Promega #E152A; 10 ml Promega luciferase assay buffer per 7 mg Promega luciferase assay substrate).

Luminescence was measured on an automated 96-well luminometer, and was expressed as either picograms of luciferase activity per well or as picograms of luciferase activity per 5 microgram of protein.

In this assay, compound 59-0008 (3-phenylazo-1H-4,1,2-benzothiadiazine) exhibited a pattern of reactivity, as shown in Figure 1. The activity for compound 59-0008 was maximal at a concentration of approximately 3-10 μ M and, more particularly, at about 3 μ M, and thus provided a response of approximately 175 light emission units.

10 Accordingly, other tested compounds were evaluated at various concentrations, and these results were compared to the results obtained for 59-0008 at 10 μ M (which value was normalized to 100). For instance, any tested compound in Figure 2 and Figure 3 that showed greater activity than 10 μ M of 59-0008 would result in a value over 100.

15 As shown in Figure 2 (39 sheets) and Figure 3 (10 sheets), several compounds were found to be particularly effective.

Example 3

In vivo Calvarial Bone Growth Data

Compound 59-0008 was assayed *in vivo* according to the procedure described 20 previously (see "In vivo Assay of Effects of Compounds on Murine Calvarial Bone Growth", *supra*). As compared to a vehicle control, compound 59-0008 induced a 4-fold increase in width of new calvarial bone.

Example 4

Chondrogenic Activity

Compounds 59-008, 59-0102 and 50-0197 were assayed for effects on the differentiation of cartilage cells, as compared to the action of recombinant human BMP-2. Briefly, a mouse clonal chondrogenic cell line, TMC-23, was isolated and cloned from costal cartilage of transgenic mice containing the BMP-2 gene control region driving SV-30 40 large T-antigen, generated as described in Ghosh-Choudhury *et al* *Endocrinology* 137:331-39, 1996. These cells were cultured in DMEM/10% FCS, and were shown to

express T-antigen, and also to produce aggrecan (toluidine blue staining at pH 1.0) and Type-II collagen (immunostaining) by 7 days after confluence.


- For measurement of alkaline phosphatase (ALP) activity, the technique of LF Bonewald *et al. J Biol Chem* (1992) 267:8943-49, was employed. Briefly, TMC-23 cells
5 were plated in 96 well microtiter plates in DMEM containing 10% FCS at 4×10^3 cells/well. Two days after plating, the cells were confluent and the medium was replaced with fresh medium containing 10% FCS and different concentrations of compounds or recombinant BMP-2. After an additional 2 or 5 days incubation, the plates were washed twice with PBS, and then lysing solution (0.05% Triton X-100) was added (100 μ l/well).
10 The cells were lysed by three freeze-thaw cycles of -70°C (30 min), followed by 37°C (30 min with shaking). Twenty microliters of cell lysates were assayed with 80 μ l of 5 mM p-nitrophenol phosphate in 1.5 M 2-amino-2-methyl-propanol buffer, pH 10.3 (Sigma ALP kit, Sigma Chemical Co., St. Louis, MO) for 10 min at 37°C. The reaction was stopped by the addition of 100 μ l of 0.5 M NaOH. The spectrophotometric absorbance at 405 nm was
15 compared to that of p-nitrophenol standards to estimate ALP activity in the samples. The protein content of the cell lysates was determined by the Bio-Rad protein assay kit (Bio-Rad, Hercules, CA). Specific activity was calculated using these two parameters.

At day 2, compounds 59-0008 (10^{-9} M), 59-0102 (10^{-7} M) and 59-0197 (10^{-9} M) increased ALP levels approximately 3-, 2- and 2.5-fold, respectively, as compared to the vehicle control. Recombinant BMP2 at 100, 50 or 10 ng/ml induced ALP levels approximately 10-, 4- or 1.5-fold, respectively, as compared to the vehicle control.
20

From the foregoing, it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications
25 may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.

Claims


1. A method to treat a condition in a vertebrate animal characterized by a deficiency in, or need for, bone growth replacement and/or an undesirable level of bone resorption, which method comprises administering to a vertebrate subject in need of such treatment an effective amount of a compound of the formula:



wherein R^a is a non-interfering substituent;
 10 m is an integer of 0-4;
 each dotted line represents an optional π -bond;
 each Z is independently N, NR, O, S, CR or CR₂, where each R is independently H or alkyl (1-6C);
 X is O, S, SO or SO₂;
 15 L is a flexible linker; and
 Ar^2 is a substituted or unsubstituted 6-membered aromatic ring.

2. The method of claim 1 wherein L is a flexible conjugated linker.
 20 3. The method of claim 1 wherein L is selected from the group consisting of a covalent bond, -N=N-, -RC=CR-, -RC=N-, -N=CR-, -NRCO-, -CONR-, -CR₂O-, and -CR₂NR- where each R is independently H or alkyl (1-6C).

4. The method of claim 1 wherein Ar^2 is



25

where R^b is a non-interfering substituent and n is an integer from 0 to 5.


5. The method of claim 4 wherein Ar² is unsubstituted phenyl.

6. The method of claim 1 wherein said compound is 59-0008.

5

7. A pharmaceutical composition for use in a method to treat a condition in a vertebrate animal characterized by a deficiency in, or need for, bone growth replacement and/or an undesirable level of bone resorption,

10 which composition comprises a pharmaceutically acceptable excipient and an effective amount of a compound of the formula:



wherein R^a is a non-interfering substituent;

m is an integer of 0-4;

each dotted line represents an optional π-bond;

15 each Z is independently N, NR, O, S, CR or CR₂, where each R is independently H or alkyl (1-6C);

X is O, S, SO or SO₂;

L is a flexible linker; and

Ar² is a substituted or unsubstituted 6-membered aromatic ring.

20

8. The composition of claim 7 wherein L is a flexible conjugated linker.


9. The composition of claim 7 wherein L is selected from the group consisting of a covalent bond, -N=N-, -RC=CR-, -RC=N-, -N=CR-, -NRCO-, -CONR-, -CR₂O, and
25 -CR₂NR- where each R is independently H or alkyl (1-6C).

10. The composition of claim 7 wherein Ar² is



wherein R^b is a non-interfering substituent and n is an integer from 0 to 5.

11. The composition of claim 7 wherein Ar^2 is unsubstituted phenyl.
5
12. The composition of claim 7 wherein said compound is 59-0008.
13. A method to treat a condition in a vertebrate animal characterized by a deficiency in, or need for, bone growth replacement and/or an undesirable level of bone
10 resorption, which method comprises administering to a vertebrate subject in need of such treatment an effective amount of a compound of the formula:



15 wherein R^a is a non-interfering substituent;
n is an integer of 0 and 5;
L is a flexible linker which does not contain nitrogen; and
Ar² is a substituted or unsubstituted phenyl or a substituted or unsubstituted naphthyl.


20 14. The method of claim 13 wherein R^a is -NR₂ or -COOR, where R is H or alkyl (1-6C).

15. The method of claim 13 wherein Ar^2 is substituted or unsubstituted phenyl.

25 16. The method of claim 13 wherein Ar^1 and Ar^2 are different.

17. A pharmaceutical composition for use in a method to treat a condition in a vertebrate animal characterized by a deficiency in, or need for, bone growth replacement and/or an undesirable level of bone resorption,

5 which composition comprises a pharmaceutically acceptable excipient and an effective amount of a compound of the formula:



wherein R^a is a non-interfering substituent;

n is an integer of 0 and 5;

10 L is a flexible linker which does not contain nitrogen; and


Ar² is a substituted or unsubstituted phenyl or a substituted or unsubstituted naphthyl.

18. The composition of claim 17 wherein R^a is -NR₂ or -COOR, where R is H
15 or alkyl (1-6C).

19. The composition of claim 17 wherein Ar² is substituted or unsubstituted phenyl.

20. The composition of claim 17 wherein Ar¹ and Ar² are different.

21. A method to treat a condition in a vertebrate animal characterized by a deficiency in, or need for, bone growth replacement and/or an undesirable level of bone resorption, which method comprises administering to a vertebrate subject in need of such treatment an effective amount of a compound of the formula:



wherein R^a is a non-interfering substituent;
n is an integer of 0 and 5;
L is a constrained linker; and
Ar² is a substituted or unsubstituted phenyl or a substituted or unsubstituted
5 naphthyl.

22. The method of claim 21 wherein R¹ is -NR₂ or -COOR, where R is H or alkyl (1-6C).

10 23. The method of claim 21 wherein Ar² is substituted or unsubstituted phenyl.

24. A pharmaceutical composition for use in a method to treat a condition in a vertebrate animal characterized by a deficiency in, or need for, bone growth replacement and/or an undesirable level of bone resorption,

15 which composition comprises a pharmaceutically acceptable excipient and an effective amount of a compound of the formula:



wherein R^a is a non-interfering substituent;

20 n is an integer of 0 and 5;
L is a constrained linker; and
Ar² is a substituted or unsubstituted phenyl or a substituted or unsubstituted
naphthyl.

25 25. The composition of claim 24 wherein R¹ is -NR₂ or -COOR, where R is H or alkyl (1-6C).

26. The composition of claim 24 wherein Ar² is substituted or unsubstituted phenyl.

27. The method of any of claims 1, 13 or 21 wherein said condition is osteoporosis, bone fracture or deficiency, primary or secondary hyperparathyroidism, periodontal disease or defect, metastatic bone disease, osteolytic bone disease, post-plastic surgery, post-prosthetic joint surgery, or post-dental implantation.

28. The method of any of claims 1, 13 or 21 which further comprises administering to said subject one or more agents that promote bone growth or that inhibit bone resorption.

10

29. The method of claim 28 wherein said agents are selected from the group consisting of bone morphogenetic factors, anti-resorptive agents, osteogenic factors, cartilage-derived morphogenic proteins, growth hormones, and differentiating factors.

1 / 5 0

2T3L-C8 CELLS		10/1/96				
5x 10 ³ Cells/well		READ 1	READ 2	AVERAGE	INDUCTION	AVE-BASAL % MAX
uM						
OS-8	100.000	0.21	0.22	0.22	0.18	-0.99 -17.80
	31.250	3.98	4.44	4.20	3.49	3.00 54.26
	9.766	6.99	6.46	6.72	5.59	5.52 100.00
	3.052	4.62	4.88	4.75	3.95	3.55 64.22
	0.954	3.13	3.16	3.14	2.61	1.94 35.12
	0.298	2.75	2.59	2.67	2.22	1.47 26.58
	0.0091	2.10	2.04	2.07	1.72	0.87 15.77
	0.029	1.56	1.71	1.63	1.36	0.43 7.80
	0.0091	1.45	1.42	1.44	1.19	0.23 4.21
	0.0028	1.28	1.37	1.33	1.10	0.12 2.25
	0.0000	1.32	1.30	1.31		
	0.0000	1.20	1.00	1.10		
		AVERAGE BASAL		1.20		

OS-8 DOSE RESPONSE




Figure 1

2 / 50









	21.433		69.74
	233.289	4.287	31.59
		0.857	39.70
		0.171	18.29
			
92-6363			
92-6363	155.199	μM	
	31.040		204.14
	322.166	15.520	154.94
		3.104	28.09
		1.552	
		0.310	3.53
			
92-8007			
92-8007	181.813	μM	-16.65
	36.323		58.65
	275.311	18.161	142.33
		3.632	45.65
		1.816	
		0.363	4.47
			
92-8215			
92-8215	165.123	μM	32.90
	33.025		151.08
	302.805	16.512	132.29
		3.302	59.90
		1.651	
		0.330	23.34

Figure 3

3 / 50

		
92-8258		
	162.102 μ M	
	32.420	
	308.447	16.210
	3.242	
	1.621	
	0.324	
		12.78
		
92-8362		
	154.647 μ M	
	30.929	
	323.318	15.465
	3.023	
	1.546	
	0.309	
		0.41
		
92-8372		
	150.046 μ M	
	30.009	
	333.234	15.004
	3.001	
	1.500	
	0.300	
		13.20
		
92-9183		

4 / 5 0



850-7377

850-7377

131.062 μM

13.106

381.488

2.621

0.524

0.1051


50.32

68.27

116.61

61.26

35.86



850-7413

850-7413

111.964 μM

11.196

446.572

2.239

0.448

0.090

-0.44

-2.55

157.01

78.73

23.91

850-7449

850-7449

69.908 μM

6.994

714.923

1.339

0.280

0.058




-42.42

73.79




112.16

75.24

26.38




	=		
850-9287			
850-9287	147.170 μ M		-15.82
	14.717		15.82
	339.744	2.943	130.71
	0.589		91.11
	0.118		69.05
			
850-9356			
850-9356	99.506 μ M		-24.650
	9.881		83.140
	502.482	1.920	168.810
	0.398		45.470
	0.080		9.740
			
850-9467			
850-9467	120.646 μ M		-19.800
	12.085		112.980
	414.436	2.413	122.730
	0.463		43.520
	0.097		33.140

6 / 50





	=		
850-9576			
850-9576	111.724 μM		
	11.172		
447 532	2.234		
	0.447		
	0.069		
			
825-0262			
825-0262	165.019 μM		
	33.204		
301.169	16.602		
	3.320		
	0.332		
			
825-0263			
825-0263	128.383 μM		
	25.677		
389.468	12.638		
	2.568		
	0.257		

	-27.430
	90.580
	101.810
	44.900
	19.930
	-19.18
	-12.60
	140.28
	-2.23
	3.07
	-18.87
	40.25
	169.96
	195.29
	14.02

7 / 50




	=			
895-0594				
895-0594	120.896 μM			
	12.090			
	413.581	2.418		
		0.484		
		0.097		
				
895-0857				
895-0857	159.028 μM			
	15.903			
	314.407	3.161		
		0.636		
		0.127		
				
895-0984				
895-0984	162.655 μM			
	16.265			
	307.363	3.253		
		0.651		
		0.130		




8 / 50

		
895-1161		
895-1161	152.623 μM	
	15.2631	
	327.6021	3.0531
	0.6111	
	0.1221	
		
895-1420		
895-1420	220.965 μM	
	22.0971	
	228.2791	4.4191
	0.8841	
	0.1771	
		
895-1679		
895-1679	180.910 μM	
	18.0811	
	278.3631	3.6181
	0.7241	
	0.1461	
		
895-1691		
895-1691	182.922 μM	
	18.2921	
	273.341	3.6581




	5.51	
	108.31	
	56.06	
	29.40	
	24.71	
	.1947	
	110.90	
	49.94	
	33.65	
	20.06	
	30.36	
	111.72	
	102.63	
	18.01	
	0.44	
	-18.29	
	50.84	
	105.70	

9 / 50

	
895-3846	
895-3846	193.267 μ M
	19.3271
258.708	3.8651
	0.7731
	0.1551
	
895-4642	
895-4642	176.473 μ M
	17.6471
283.331	3.5251
	0.7061
	0.1411
	
895-4843	
895-4843	159.581 μ M
	15.9581
313.3121	3.1921
	0.6361
	0.1261
	
895-5185	
895-5185	162.433 μ M
	16.2431
307.621	3.2481
	0.6501
	0.1301

			
625-6862			
625-6862	165.876 μM		54.72
	16.588		150.21
	301.43	3.318	113.97
		0.684	41.98
		0.133	38.28
			
625-6863			
625-6863	113.552 μM		-20.87
	11.355		201.56
	440.326	2.271	12.95
		0.454	0.82
		0.091	0.68
			
625-6866			
625-6866	178.349 μM		-29.16
	17.835		0.62
	280.349	3.587	182.84
		0.713	118.55
		0.143	42.75

11 / 50

	404.9791	2.191		108.84
	—	0.430		108.12
	—	0.086		37.16
				
598-0330				
598-0330		128.718 μ M		-16.80
		12.872		67.23
	388.445	2.574		210.25
		0.515		73.35
		0.103		28.25
				
598-0333				
598-0335		132.810 μ M		-10.41
		13.281		73.84
	378.4781	2.689		198.80
		0.531		102.12
		0.108		35.72
				
598-0354				
598-0354		121.469 μ M		-16.32
		12.150		103.48
	411.5271	2.430		115.43
		0.486		53.88
		0.097		27.03











NNC#	MOL WEIGHT	Concentration	% Response
	430.33		
50-0194	100.00 μM	-19.190	
	31.25 μM	32.450	
	9.77 μM	-14.240	
	3.05 μM	-11.330	
	953.67 nM	-12.790	
	298.02 nM	-13.450	
	93.13 nM	-12.290	
	29.10 nM	-9.440	
	9.09 nM	-6.450	
	2.84 nM	-8.130	
	888.18 pM	-3.320	
	275.36		
50-0195	100.00 μM	-4.630	
50-0195	31.25 μM	16.790	
	9.77 μM	62.830	
	3.05 μM	102.720	
	953.67 nM	60.860	
	298.02 nM	32.450	
	93.13 nM	19.340	
	29.10 nM	17.220	
	9.09 nM	5.640	
	2.84 nM	4.840	
	888.18 pM	5.640	
	276.30		
50-0196	100.00 μM	-16.210	
50-0196	31.25 μM	-8.560	
	9.77 μM	11.620	
	3.05 μM	27.780	
	953.67 nM	18.390	
	298.02 nM	6.230	
	93.13 nM	12.420	
	29.10 nM	12.630	
	9.09 nM	6.590	
	2.84 nM	7.970	
	888.18 pM	5.060	

Figure 2




				
50-0197	274.37			
50-0197		100.00 μM	-18.250	
		31.25 μM	-14.980	
		9.77 μM	4.040	
		3.05 μM	93.790	
		953.67 nM	205.530	
		298.02 nM	242.920	
		93.13 nM	195.890	
		29.10 nM	115.320	
		9.09 nM	85.630	
		2.84 nM	54.380	
		888.18 pM	33.180	
				
59-0008	254.32			
				
59-0019	59-0019			
59-0019		100.00 μM	-22.240	
		31.25 μM	-22.670	
		9.77 μM	-17.470	
		3.05 μM	74.480	
		953.67 nM	198.080	
		298.02 nM	258.340	
		93.13 nM	225.350	
		29.10 nM	75.220	
		9.09 nM	24.030	
		2.84 nM	34.480	
		888.18 pM	-3.740	
				
59-0020	266.73			
59-0020		100.00 μM	-16.510	
		31.25 μM	-16.040	
		9.77 μM	-0.270	
		3.05 μM	96.490	
		953.67 nM	153.320	
		298.02 nM	110.240	
		93.13 nM	60.030	

14 / 50



	29.10 nM	37.870
	9.09 nM	24.820
	2.84 nM	20.500
	888.18 pM	13.310




				
59-0021	284.72			
59-0021	100.00 μ M	-16.310		
	31.25 μ M	-12.850		
	9.77 μ M	84.130		
	3.05 μ M	89.940		
	953.67 nM	65.750		
	298.02 nM	33.940		
	93.13 nM	22.560		
	29.10 nM	25.020		
	9.09 nM	13.910		
	2.84 nM	33.270		
	888.18 pM	15.500		
				
59-0022	268.37			
59-0022	100.00 μ M	7.250		
	31.25 μ M	-2.070		
	9.77 μ M	-0.270		
	3.05 μ M	4.380		
	953.67 nM	3.080		
	298.02 nM	-1.600		
	93.13 nM	-0.200		
	29.10 nM	-3.270		
	9.09 nM	1.130		
	2.84 nM	2.590		
	888.18 pM	2.460		
				
59-0023	239.28			
59-0023	100.00 μ M	-12.720		
	31.25 μ M	33.140		
	9.77 μ M	56.500		
	3.05 μ M	29.550		
	953.67 nM	25.380		
	298.02 nM	15.700		
	93.13 nM	7.380		
	29.10 nM	9.710		
	9.09 nM	1.000		
	2.84 nM	4.520		
	888.18 pM	-0.010		




16 / 50

					
59-0024	220.28				
					
59-0025	224.31				
59-0025		100.00 μM	-25.590		
		31.25 μM	14.150		
		9.77 μM	50.690		
		3.05 μM	57.880		
		953.67 nM	38.900		
		298.02 nM	28.530		
		93.13 nM	19.660		
		29.10 nM	17.490		
		9.09 nM	-0.600		
		2.84 nM	-4.190		
		888.18 pM	4.670		
					
59-0026	248.29				
59-0026		100.00 μM	-29.830		
		31.25 μM	-9.440		
		9.77 μM	-10.470		
		3.05 μM	46.220		
		953.67 nM	107.760		
		298.02 nM	86.720		
		93.13 nM	36.850		
		29.10 nM	26.720		
		9.09 nM	8.520		
		2.84 nM	-1.240		
		888.18 pM	4.020		

17 / 50




				
59-0027	250.30			
59-0027		100.00 uM	89.810	
		31.25 uM	54.670	
		9.77 uM	44.940	
		3.05 uM	23.780	
		953.67 nM	8.380	
		298.02 nM	6.330	
		93.13 nM	7.360	
		29.10 nM	3.380	
		9.09 nM	-1.620	
		2.84 nM	-3.670	
		888.18 pM	-0.720	
				
59-0028	226.28			
59-0028		100.00 uM	-26.750	
		31.25 uM	-16.740	
		9.77 uM	29.550	
		3.05 uM	100.580	
		953.67 nM	54.940	
		298.02 nM	31.340	
		93.13 nM	7.500	
		29.10 nM	7.500	
		9.09 nM	7.880	
		2.84 nM	3.140	
		888.18 pM	4.670	




					
59-0029	249.27				
59-0029	100.00 μM	-15.160			
	31.25 μM	41.940			
	9.77 μM	36.630			
	3.05 μM	7.120			
	953.67 nM	21.880			
	298.02 nM	15.540			
	93.13 nM	1.810			
	29.10 nM	1.370			
	9.09 nM	12.140			
	2.84 nM	-4.230			
	888.18 pM	9.040			
					
59-0030	233.28				
59-0030	100.00 μM	-27.970			
	31.25 μM	-22.830			
	9.77 μM	-5.420			
	3.05 μM	57.280			
	953.67 nM	72.620			
	298.02 nM	53.000			
	93.13 nM	29.990			
	29.10 nM	14.630			
	9.09 nM	3.870			
	2.84 nM	6.970			
	888.18 pM	1.810			
					
59-0031	231.30				
59-0031	100.00 μM	-25.790			
	31.25 μM	-17.810			
	9.77 μM	20.840			
	3.05 μM	87.380			
	953.67 nM	49.320			
	298.02 nM	43.110			
	93.13 nM	29.530			
	29.10 nM	1.810			
	9.09 nM	1.220			
	2.84 nM	-0.550			
	888.18 pM	4.160			




	248.29				
59-0032					
	100.00 μM	-7.780			
	31.25 μM	40.750			
	9.77 μM	42.820			
	3.05 μM	25.700			
	953.67 nM	31.170			
	298.02 nM	34.410			
	93.13 nM	3.570			
	29.10 nM	4.320			
	9.09 nM	-10.000			
	2.84 nM	5.650			
	888.18 pM	11.990			
	248.29				
59-0033					
	100.00 μM	-28.180			
	31.25 μM	-11.590			
	9.77 μM	55.300			
	3.05 μM	49.710			
	953.67 nM	47.410			
	298.02 nM	0.250			
	93.13 nM	7.980			
	29.10 nM	-8.940			
	9.09 nM	-7.630			
	2.84 nM	-0.400			
	888.18 pM	-5.980			
	268.34				
59-0034					
	100.00 μM	-28.51			
	31.25 μM	241			
	9.77 μM	73.58			
	3.05 μM	37.91			
	953.67 nM	20.09			
	298.02 nM	16.87			
	93.13 nM	15.23			
	29.10 nM	28.83			
	9.09 nM	9.08			
	2.84 nM	-23.02			
	888.18 pM	-0.32			

20 / 50




<chem>CN(C)c1ccc(NC(=O)c2cc3c(cc2)nc4ccccc3n2)cc1</chem>	291.36			
59-0035	100.00 μM	-14.92		
	31.25 μM	29.17		
	9.77 μM	15.87		
	3.05 μM	18.81		
	953.67 nM	3.88		
	298.02 nM	6.15		
	93.13 nM	3.22		
	29.10 nM	-10.03		
	9.09 nM	15.58		
	2.84 nM	-3.56		
	888.18 pM	-7.13		
<chem>CNCCc1ccc(NC(=O)c2cc3c(cc2)nc4ccccc3n2)cc1</chem>	262.31			
59-0036	100.00 μM	-0.98		
	31.25 μM	-3.25		
	9.77 μM	-4.54		
	3.05 μM	-1.95		
	953.67 nM	0.32		
	298.02 nM	-6.49		
	93.13 nM	-17.19		
	29.10 nM	-0.66		
	9.09 nM	-5.52		
	2.84 nM	-9.41		
	888.18 pM	-16.53		
<chem>CN(C)c1c(O)c2c(c1)nc3ccccc2n3C(=O)N4C=CC=C4</chem>	308.00			
59-0037	100.00 μM	-10.69		
	31.25 μM	-11.99		
	9.77 μM	-10.03		
	3.05 μM	-19.11		
	953.67 nM	-9.41		
	298.02 nM	2.27		
	93.13 nM	-2.91		
	29.10 nM	-10.69		
	9.09 nM	2.59		
	2.84 nM	0.66		
	888.18 pM	-2.59		

					
59-0038	291.36				
59-0038		100.00 μM	-23.430		
		31.25 μM	-8.390		
		9.77 μM	-0.100		
		3.05 μM	-2.860		
		953.67 nM	-2.240		
		298.02 nM	3.900		
		93.13 nM	6.350		
		29.10 nM	1.150		
		9.09 nM	6.960		
		2.84 nM	-4.390		
		888.18 pM	-0.380		
					
59-0039	312.35				
59-0039		100.00 μM	14.170		
		31.25 μM	7.620		
		9.77 μM	1.940		
		3.05 μM	-3.140		
		953.67 nM	-7.770		
		298.02 nM	-5.980		
		93.13 nM	-8.820		
		29.10 nM	-2.390		
		9.09 nM	-16.580		
		2.84 nM	-4.480		
		888.18 pM	-0.450		
					
59-0040	290.37				
59-0040		100.00 μM	-20.400		
		31.25 μM	-17.310		
		9.77 μM	-8.110		
		3.05 μM	32.180		
		953.67 nM	36.180		
		298.02 nM	17.440		
		93.13 nM	2.040		
		29.10 nM	10.350		
		9.09 nM	-8.070		
		2.84 nM	6.960		
		888.18 pM	13.440		



				
59-0041	501.90			
59-0041	100.00 μM	-18.37		
	31.25 μM	-17.33		
	9.77 μM	-5.11		
	3.05 μM	3.31		
	953.67 nM	-0.77		
	298.02 nM	-1.56		
	93.13 nM	3.55		
	29.10 nM	-11.24		
	9.09 nM	0.25		
	2.84 nM	-0.27		
	888.18 pM	2.02		
				
59-0042	281.36			
59-0042	100.00 μM	163.51		
	31.25 μM	-7.67		
	9.77 μM	9.41		
	3.05 μM	0.75		
	953.67 nM	6.11		
	298.02 nM	3.82		
	93.13 nM	2.54		
	29.10 nM	4.07		
	9.09 nM	-9.73		
	2.84 nM	-0.02		
	888.18 pM	18.37		
				
59-0043	280.29			
59-0043	100.00 μM	20.66		
	31.25 μM	7.4		
	9.77 μM	-1.29		
	3.05 μM	-2.31		
	953.67 nM	1.54		
	298.02 nM	-0.79		
	93.13 nM	1.52		
	29.10 nM	2.79		
	9.09 nM	-0.27		
	2.84 nM	8.92		
	888.18 pM	-4.34		

				
59-0044	341.21			
59-0044	100.00 μM	7.38		
	31.25 μM	11.72		
	9.77 μM	12.49		
	3.05 μM	-0.52		
	953.67 nM	0.51		
	298.02 nM	6.11		
	93.13 nM	-1.54		
	29.10 nM	19.14		
	9.09 nM	7.13		
	2.84 nM	-2.06		
	888.18 pM	5.84		
				
59-0045	283.33			
59-0045	100.00 μM	52.37	64.460	
	31.25 μM	148.43	192.960	
	9.77 μM	204.47	422.540	
	3.05 μM	280.3	437.020	
	953.67 nM	254.82	410.890	
	298.02 nM	218.21	266.090	
	93.13 nM	198.98	183.730	
	29.10 nM	96.06	80.440	
	9.09 nM	67.35	55.530	
	2.84 nM	52.99	44.160	
				
59-0046	389.37			
59-0046	100.00 μM	79.33		
	31.25 μM	2.24		
	9.77 μM	-1.67		
	3.05 μM	-6.18		
	953.67 nM	0.001		
	298.02 nM	-3.63		
	93.13 nM	-0.84		
	29.10 nM	-8.42		
	9.09 nM	3.92		
	2.84 nM	0.31		
	888.18 pM	5.61		



24 / 50




	59-0047	303.37				
	59-0047		100.00 μM	-6.73		
			31.25 μM	10.38		
			9.77 μM	-6.16		
			3.05 μM	-1.39		
			953.67 nM	-10.11		
			298.02 nM	-4.49		
			93.13 nM	-7.28		
			29.10 nM	-12.34		
			9.09 nM	-3.08		
			2.84 nM	-2.26		
			888.18 pM	-5.34		
	59-0048	384.50				
	59-0048		100.00 μM	-6.73		
			31.25 μM	0.27		
			9.77 μM	-5.61		
			3.05 μM	-2.26		
			953.67 nM	-12.89		
			298.02 nM	-1.69		
			93.13 nM	-4.77		
			29.10 nM	-8.14		
			9.09 nM	-3.92		
			2.84 nM	-11.2		
			888.18 pM	-4.77		
	59-0049	251.29				
	59-0049		100.00 μM	4.49		
			31.25 μM	0		
			9.77 μM	-4.77		
			3.05 μM	1.96		
			953.67 nM	8.69		
			298.02 nM	-5.04		
			93.13 nM	-2.24		
			29.10 nM	1.69		
			9.09 nM	-4.49		
			2.84 nM	2.24		
			888.18 pM	-0.31		




25 / 50




					
59-0050	303.36				
59-0050		100.00 uM	45.79		
		31.25 uM	10.02		
		9.77 uM	11.29		
		3.05 uM	-4.68		
		953.67 nM	-6.92		
		298.02 nM	-5.65		
		93.13 nM	1.69		
		29.10 nM	-7.57		
		9.09 nM	-12.05		
		2.84 nM	-13.63		
		888.18 pM	5.21		
					
59-0051	251.35				
59-0051		100.00 uM	32.36		
		31.25 uM	-18.42		
		9.77 uM	-0.55		
		3.05 uM	-13.94		
		953.67 nM	-12.02		
		298.02 nM	-14.59		
		93.13 nM	-7.55		
		29.10 nM	-11.4		
		9.09 nM	-14.91		
		2.84 nM	-10.74		
		888.18 pM	-20.03		

26 / 50




					
59-0052	393.28				
59-0052		100.00 μM	-21.62		
		31.25 μM	-13.32		
		9.77 μM	-21.31		
		3.05 μM	-11.08		
		953.67 nM	-20.66		
		298.02 nM	-17.14		
		93.13 nM	-16.49		
		29.10 nM	-11.4		
		9.09 nM	-10.74		
		2.84 nM	-11.08		
		888.18 pM	-14.59		
					
59-0053	354.41				
59-0053		100.00 μM	-17.14		
		31.25 μM	-21.31		
		9.77 μM	-9.47		
		3.05 μM	-11.08		
		953.67 nM	-0.83		
		298.02 nM	-11.4		
		93.13 nM	-9.47		
		29.10 nM	-19.72		
		9.09 nM	-18.45		
		2.84 nM	-10.09		
		888.18 pM	-2.76		




				
59-0054	236.28			
59-0054	100.00 μM	-20.04		
	31.25 μM	-6.95		
	9.77 μM	8.3		
	3.05 μM	-3.37		
	953.67 nM	-2.4		
	298.02 nM	-0.99		
	93.13 nM	-0.99		
	29.10 nM	-1.94		
	9.09 nM	5.92		
	2.84 nM	-2.17		
	888.18 pM	-9.31		
				
59-0055	425.51			
59-0055	100.00 μM	-13.76		
	31.25 μM	-9.51		
	9.77 μM	-2.02		
	3.05 μM	3.24		
	953.67 nM	-6.27		
	298.02 nM	-4.05		
	93.13 nM	-1.62		
	29.10 nM	-7.49		
	9.09 nM	-7.09		
	2.84 nM	-3.04		
				
59-0056	512.34			
59-0056	100.00 μM	-1.42		
	31.25 μM	-4.87		
	9.77 μM	0.18		
	3.05 μM	3.84		
	953.67 nM	-5.07		
	298.02 nM	-7.29		
	93.13 nM	0.001		
	29.10 nM	-4.25		
	9.09 nM	-1.02		
	2.84 nM	-3.85		

	9.09 nM	8.070
	2.84 nM	0.440
		
59-0063		
59-0063	100.00 μM	-2.510
	31.25 μM	-6.130
	9.77 μM	-8.950
	3.05 μM	-8.020
	953.67 nM	-8.010
	298.02 nM	-2.520
	93.13 nM	-5.810
	29.10 nM	-3.450
	9.09 nM	-4.390
	2.84 nM	-6.280
		
59-0064		
59-0064	100.00 μM	-23.090
	31.25 μM	-21.040
	9.77 μM	78.400
	3.05 μM	155.220
	953.67 nM	113.120
	298.02 nM	30.640
	93.13 nM	15.240
	29.10 nM	22.150
	9.09 nM	-0.770
	2.84 nM	4.410
		
59-0065		
59-0065	100.00 μM	-2.030
	31.25 μM	-2.980
	9.77 μM	-15.240
	3.05 μM	-15.400
	953.67 nM	-15.240
	298.02 nM	-10.520
	93.13 nM	-13.830
	29.10 nM	-5.810
	9.09 nM	-3.620
	2.84 nM	-7.070




					
59-0066					
59-0066	100.00 μM	10.060			
	31.25 μM	2.680			
	9.77 μM	10.850			
	3.05 μM	14.610			
	953.67 nM	0.950			
	298.02 nM	3.780			
	93.13 nM	1.730			
	29.10 nM	-2.820			
	9.09 nM	-2.820			
	2.84 nM	-3.920			
					
59-0067					
59-0067	100.00 μM	-24.040			
	31.25 μM	-24.890			
	9.77 μM	-1.450			
	3.05 μM	60.900			
	953.67 nM	133.860			
	298.02 nM	75.330			
	93.13 nM	28.760			
	29.10 nM	20.070			
	9.09 nM	4.980			
	2.84 nM	4.450			
					
59-0068					
59-0068	100.00 μM	-22.130			
	31.25 μM	-7.880			
	9.77 μM	93.900			
	3.05 μM	81.060			
	953.67 nM	22.330			
	298.02 nM	17.300			
	93.13 nM	8.460			
	29.10 nM	-3.530			
	9.09 nM	-4.230			
	2.84 nM	-6.140			





30 / 50




				
59-0069				
59-0069	100.00 μM	5.490		
	31.25 μM	9.670		
	9.77 μM	16.090		
	3.05 μM	-7.180		
	953.67 nM	-2.840		
	298.02 nM	-3.710		
	93.13 nM	-11.180		
	29.10 nM	-5.790		
	9.09 nM	-7.180		
	2.84 nM	-4.750		
				
59-0070				
59-0070	100.00 μM	-25.930		
	31.25 μM	-23.000		
	9.77 μM	36.060		
	3.05 μM	214.280		
	953.67 nM	158.530		
	298.02 nM	72.890		
	93.13 nM	20.940		
	29.10 nM	7.760		
	9.09 nM	7.590		
	2.84 nM	-8.400		
				
59-0071				
59-0071	100.00 μM	-18.650		
	31.25 μM	-15.540		
	9.77 μM	17.060		
	3.05 μM	176.090		
	953.67 nM	76.070		
	298.02 nM	31.260		
	93.13 nM	16.410		
	29.10 nM	4.870		
	9.09 nM	-7.330		
	2.84 nM	-4.660		




				
59-0072				
	100.00 μM	-19.750		
	31.25 μM	-18.650		
	9.77 μM	-18.430		
	3.05 μM	-15.770		
	953.67 nM	9.970		
	298.02 nM	74.740		
	93.13 nM	175.430		
	29.10 nM	213.580		
	9.09 nM	164.320		
	2.84 nM	119.100		
	888.18 pM	60.770		
				
59-0073				
	100.00 μM	-3.010		
	31.25 μM	-4.830		
	9.77 μM	-9.660		
	3.05 μM	-4.680		
	953.67 nM	-6.500		
	298.02 nM	-2.510		
	93.13 nM	7.140		
	29.10 nM	0.97		
	9.09 nM	-5.5		
	2.84 nM	5.3		
				
59-0074				
	100.00 μM	-2.85		
	31.25 μM	2.14		
	9.77 μM	-4.85		
	3.05 μM	-3.5		
	953.67 nM	-4.85		
	298.02 nM	9.95		
	93.13 nM	4.47		
	29.10 nM	-8		
	9.09 nM	-4.17		
	2.84 nM	6.97		





32 / 50




				
59-0075				
59-0075	100.00 μM	-0.68		
	31.25 μM	-10.16		
	9.77 μM	-5.35		
	3.05 μM	-6.5		
	953.67 nM	-0.85		
	298.02 nM	5.97		
	93.13 nM	0.97		
	29.10 nM	-2.35		
	9.09 nM	0.32		
	2.84 nM	10.47		
				
59-0076				
59-0076	100.00 μM	-19.12		
	31.25 μM	9.29		
	9.77 μM	10.63		
	3.05 μM	22.43		
	953.67 nM	19.93		
	298.02 nM	3.47		
	93.13 nM	19.93		
	29.10 nM	10.63		
	9.09 nM	14.28		
	2.84 nM	11.3		
				
59-0077				
59-0077	100.00 μM	-20.96		
	31.25 μM	-16.23		
	9.77 μM	-10.58		
	3.05 μM	-11.96		
	953.67 nM	-19.44		
	298.02 nM	-17.3		
	93.13 nM	-13.79		
	29.10 nM	-15.62		
	9.09 nM	-14.09		
	2.84 nM	-14.4		





				
59-0078				
	100.00 μM	-26.540		
	31.25 μM	-22.560		
	9.77 μM	71.530		
	3.05 μM	207.960		
	953.67 nM	379.230		
	298.02 nM	241.460		
	93.13 nM	138.100		
	29.10 nM	84.020		
	9.09 nM	50.350		
	2.84 nM	56.600		
	0.80 nM	92.520		
				
59-0079				
59-0079	100.00 μM	-34.980		
	31.25 μM	-21.390		
	9.77 μM	37.200		
	3.05 μM	122.580		
	953.67 nM	69.010		
	298.02 nM	64.000		
	93.13 nM	46.490		
	29.10 nM	30.310		
	9.09 nM	33.490		
	2.84 nM	29.760		
				
59-0080				
59-0080	100.00 μM	5.390		
	31.25 μM	5.560		
	9.77 μM	6.440		
	3.05 μM	2.440		
	953.67 nM	-5.030		
	298.02 nM	7.680		
	93.13 nM	-3.630		
	29.10 nM	3.650		
	9.09 nM	1.050		
	2.84 nM	6.940		
				—
59-0084				




59-0081		100.00 μM	62.840
		31.25 μM	11.300
		9.77 μM	-8.670
		3.05 μM	2.440
		953.67 nM	-5.200
		298.02 nM	-2.080
		93.13 nM	1.220
		29.10 nM	-2.250
		9.09 nM	1.050
		2.84 nM	-3.300
			
59-0082		100.00 μM	111.79
		31.25 μM	62.68
		9.77 μM	32.36
		3.05 μM	9.11
		953.67 nM	-10.62
		298.02 nM	-1.88
		93.13 nM	-8.89
		29.10 nM	-3.91
		9.09 nM	2.22
		2.84 nM	16.36
			
59-0083		100.00 μM	48.93
		31.25 μM	40.91
		9.77 μM	25.85
		3.05 μM	17.85
		953.67 nM	8.55
		298.02 nM	3.91
		93.13 nM	2.05
		29.10 nM	7.99
		9.09 nM	-3.91
		2.84 nM	3.35
			
59-0084		100.00 μM	-37.670
		31.25 μM	26.050
		9.77 μM	9.210
		3.05 μM	10.070




		953.67 nM	21.700
		298.02 nM	5.900
		93.13 nM	4.870
		29.10 nM	-10.920
		9.09 nM	10.080
		2.84 nM	-2.060
	59-0085		
59-0085		100.00 μM	17.070
		31.25 μM	41.890
		9.77 μM	18.500
		3.05 μM	20.340
		953.67 nM	22.490
		298.02 nM	8.090
		93.13 nM	11.790
		29.10 nM	1.240
		9.09 nM	-0.760
		2.84 nM	5.940
	59-0086		
59-0086		100.00 μM	30.750
		31.25 μM	31.190
		9.77 μM	14.780
		3.05 μM	13.500
		953.67 nM	14.080
		298.02 nM	3.940
		93.13 nM	9.370
		29.10 nM	-2.610
		9.09 nM	-5.040
		2.84 nM	1.530
	59-0087		
59-0087		100.00 μM	10.660
		31.25 μM	11.080
		9.77 μM	3.100
		3.05 μM	-1.320
		953.67 nM	17.070
		298.02 nM	7.950
		93.13 nM	-4.460
		29.10 nM	4.510
		9.09 nM	-0.470
		2.84 nM	9.680

					
59-0088					
59-0088	100.00 μM				
	31.25 μM				
	9.77 μM				
	3.05 μM				
	953.67 nM				
	298.02 nM				
	93.13 nM				
	29.10 nM				
	9.09 nM				
	2.84 nM				
					
59-0089					
59-0089	100.00 μM	60.09			
	31.25 μM	116.25			
	9.77 μM	65.84			
	3.05 μM	36.1			
	953.67 nM	37.96			
	298.02 nM	18.42			
	93.13 nM	6.33			
	29.10 nM	13.58			
	9.09 nM	0.75			
	2.84 nM	-5.77			
					
59-0090					
59-0090	100.00 μM	32.77			
	31.25 μM	24.63			
	9.77 μM	19.5			
	3.05 μM	41.31			
	953.67 nM	9.81			
	298.02 nM	-1.76			
	93.13 nM	3.53			
	29.10 nM	2.95			
	9.09 nM	2.95			
	2.84 nM	7.8			
					
59-0091					
59-0091	100.00 μM	0.26			
	31.25 μM	13.54			




		9.77 μ M	95.94
		3.05 μ M	87.71
		953.67 nM	44.17
		298.02 nM	38.26
		93.13 nM	23.87
		29.10 nM	21.65
		9.09 nM	10.95
		2.84 nM	20.92
			
59-0092			
59-0092		100.00 μ M	-11.56
		31.25 μ M	17.84
		9.77 μ M	50.19
		3.05 μ M	25.84
		953.67 nM	14.4
		298.02 nM	6.77
		93.13 nM	8.62
		29.10 nM	2.22
		9.09 nM	8.38
		2.84 nM	1
			
59-0093			
59-0093		100.00 μ M	-11.67
		31.25 μ M	15.02
		9.77 μ M	35.44
		3.05 μ M	29.89
		953.67 nM	22.88
		298.02 nM	19.56
		93.13 nM	5.18
		29.10 nM	7.39
		9.09 nM	4.56
		2.84 nM	5.9
			
59-0094			
59-0094		100.00 μ M	-17.69
		31.25 μ M	45.15
		9.77 μ M	24.97
		3.05 μ M	19.81
		953.67 nM	9.35
		298.02 nM	1.36
		93.13 nM	9.24
		29.10 nM	-0.48
		9.09 nM	6.16
		2.84 nM	1.61

				
59-0114	475.54			
	100.00 μ M	52.030		
	31.25 μ M	36.120		
	9.77 μ M	25.840		
	3.05 μ M	16.870		
	953.67 nM	12.540		
	298.02 nM	9.420		
	93.13 nM	-1.060		
	29.10 nM	2.160		
	9.09 nM	-6.000		
	2.84 nM	2.470		
	0.80 nM	-1.460		
				
59-0115	318.87			
	100.00 μ M	73.700		
	31.25 μ M	2.770		
	9.77 μ M	-10.430		
	3.05 μ M	-12.340		
	953.67 nM	-13.750		
	298.02 nM	-13.960		
	93.13 nM	-11.940		
	29.10 nM	-9.830		
	9.09 nM	-8.820		
	2.84 nM	-0.950		
	0.80 nM	-0.050		
				
59-0116	269.30			
	100.00 μ M	31.380		
	31.25 μ M	109.060		
	9.77 μ M	231.070		
	3.05 μ M	240.670		
	953.67 nM	132.020		
	298.02 nM	75.820		
	93.13 nM	53.250		
	29.10 nM	47.500		
	9.09 nM	39.440		
	2.84 nM	42.170		
	0.80 nM	31.180		
				—
59-0117	268.38			
	100.00 μ M	-68.520		




		31.25 μM	-7.450
		9.77 μM	111.630
		3.05 μM	84.340
		953.67 nM	4.740
		298.02 nM	-19.270
		93.13 nM	-26.660
		29.10 nM	-28.880
		9.09 nM	-42.180
		2.84 nM	-41.300
		0.80 nM	-39.220
			
59-0118	313.36		
		100.00 μM	-67.170
		31.25 μM	-56.680
		9.77 μM	-58.060
		3.05 μM	-55.720
		953.67 nM	-48.200
		298.02 nM	-50.300
		93.13 nM	-33.310
		29.10 nM	-47.340
		9.09 nM	-49.310
		2.84 nM	-56.200
		0.80 nM	-57.310
			
59-0119	314.34		
		100.00 μM	167.500
		31.25 μM	-29.240
		9.77 μM	-57.800
		3.05 μM	-52.030
		953.67 nM	-54.240
		298.02 nM	-53.870
		93.13 nM	-38.110
		29.10 nM	-55.100
		9.09 nM	-52.270
		2.84 nM	-53.500
		0.80 nM	-43.650
			
59-0120	504.49		
		100.00 μM	-82.790
		31.25 μM	-80.470
		9.77 μM	-66.800
		3.05 μM	-60.790
		953.67 nM	-54.240
		298.02 nM	-45.250
		93.13 nM	-50.860

		2.84 nM	6.27
		0.80 nM	3.55
	59-0146	246.27	
		100.00 μM	-63.05
		31.25 μM	4.42
		9.77 μM	-13.73
		3.05 μM	-16.45
		953.67 nM	-35.47
		298.02 nM	-51.25
		93.13 nM	-50.13
		29.10 nM	-42.92
		9.09 nM	-45.64
		2.84 nM	-56.58
		0.80 nM	-39.68
	59-0147	314.36	
		100.00 μM	-85
		31.25 μM	-85
		9.77 μM	-80.29
		3.05 μM	-41.67
		953.67 nM	78.69
		298.02 nM	269.13
		93.13 nM	323.59
		29.10 nM	339.88
		9.09 nM	270.48
		2.84 nM	245.58
		0.80 nM	180.33
	59-0148	291.35	
		100.00 μM	-68.38
		31.25 μM	-36.33
		9.77 μM	-2.3
		3.05 μM	12.12
		953.67 nM	-2.42
		298.02 nM	-16.21
		93.13 nM	-30.87
		29.10 nM	-35.58
		9.09 nM	-39.07
		2.84 nM	-41.18
		0.80 nM	-45.53

42 / 50

						
59-0149	329.33					
	100.00 μM	-16.91				
	31.25 μM	-1.81				
	9.77 μM	-0.53				
	3.05 μM	15.29				
	953.67 nM	78.78				
	298.02 nM	163.51				
	93.13 nM	223.57				
	29.10 nM	173.93				
	9.09 nM	122.31				
	2.84 nM	98.02				
	0.80 nM	69.06				
						
59-0150	304.39					
	100.00 μM	63.32				
	31.25 μM	193.53				
	9.77 μM	419.26				
	3.05 μM	497.21				
	953.67 nM	295.19				
	298.02 nM	193.35				
	93.13 nM	99.46				
	29.10 nM	69.96				
	9.09 nM	59				
	2.84 nM	52.16				
	0.80 nM	48.75				
						
59-0151	278.311					
59-0151	100.00 μM	-6.660				
	31.25 μM	16.240				
	9.77 μM	18.300				
	3.05 μM	11.690				
	953.67 nM	8.500				
	298.02 nM	9.070				
	93.13 nM	6.110				
	29.10 nM	5.880				
	9.09 nM	7.700				
	2.84 nM	2.000				
	0.80 nM	1.210				

43 / 50





						
59-0152	266.275					
59-0152		100.00 <u>M</u>	-6.890			
		31.25 <u>M</u>	12.490			
		9.77 <u>M</u>	21.950			
		3.05 <u>M</u>	12.820			
		953.67 <u>nM</u>	7.350			
		298.02 <u>nM</u>	4.290			
		93.13 <u>nM</u>	9.750			
		29.10 <u>nM</u>	4.860			
		9.09 <u>nM</u>	1.320			
		2.84 <u>nM</u>	4.280			
		0.80 <u>nM</u>	4.160			
						
59-0153	282.73					
59-0153		100.00 <u>M</u>	-4.150			
		31.25 <u>M</u>	-0.390			
		9.77 <u>M</u>	11.120			
		3.05 <u>M</u>	14.540			
		953.67 <u>nM</u>	9.520			
		298.02 <u>nM</u>	11.570			
		93.13 <u>nM</u>	-0.160			
		29.10 <u>nM</u>	1.550			
		9.09 <u>nM</u>	-0.960			
		2.84 <u>nM</u>	4.730			
		0.80 <u>nM</u>	5.650			
						
59-0154	262.312					
59-0154		100.00 <u>M</u>	0.290			
		31.25 <u>M</u>	24.670			
		9.77 <u>M</u>	15.680			
		3.05 <u>M</u>	14.540			
		953.67 <u>nM</u>	13.170			
		298.02 <u>nM</u>	5.540			
		93.13 <u>nM</u>	2.690			
		29.10 <u>nM</u>	-1.190			
		9.09 <u>nM</u>	2.460			
		2.84 <u>nM</u>	4.170			
		0.80 <u>nM</u>	1.890			

44 / 50




59-0155	316.282					
59-0155		100.00 μM	-2.950			
		31.25 μM	1.900			
		9.77 μM	-9.450			
		3.05 μM	-0.220			
		953.67 nM	0.690			
		298.02 nM	5.090			
		93.13 nM	-3.250			
		29.10 nM	0.530			
		9.09 nM	-1.900			
		2.84 nM	9.480			
		0.80 nM	-1.130			
59-0156	333.391					
59-0156		100.00 μM	5.840			
		31.25 μM	2.050			
		9.77 μM	7.960			
		3.05 μM	6.890			
		953.67 nM	-0.370			
		298.02 nM	-1.880			
		93.13 nM	-3.550			
		29.10 nM	-7.340			
		9.09 nM	-1.590			
		2.84 nM	2.650			
		0.80 nM	2.500			
59-0157	290.366					
59-0157		100.00 μM	-6.440			
		31.25 μM	14.920			
		9.77 μM	19.930			
		3.05 μM	11.440			
		953.67 nM	8.570			
		298.02 nM	-7.190			
		93.13 nM	0.080			
		29.10 nM	-0.230			
		9.09 nM	-4.460			
		2.84 nM	2.200			
		0.80 nM	9.920			




45 / 50

59-0158	308.337					
59-0158		100.00 μM	-5.980			
		31.25 μM	3.720			
		9.77 μM	16.140			
		3.05 μM	27.060			
		953.67 nM	9.930			
		298.02 nM	11.900			
		93.13 nM	2.810			
		29.10 nM	3.110			
		9.09 nM	0.690			
		2.84 nM	1.900			
		0.80 nM	7.970			
59-0159	308.337					
59-0159		100.00 μM	2.790			
		31.25 μM	13.530			
		9.77 μM	4.700			
		3.05 μM	10.910			
		953.67 nM	2.800			
		298.02 nM	9.710			
		93.13 nM	4.830			
		29.10 nM	0.650			
		9.09 nM	5.900			
		2.84 nM	6.610			
		0.80 nM	6.250			
59-0160	319.408					
59-0160		100.00 μM	-5.060			
		31.25 μM	-3.390			
		9.77 μM	5.300			
		3.05 μM	15.910			
		953.67 nM	6.610			
		298.02 nM	11.380			
		93.13 nM	4.460			
		29.10 nM	3.520			
		9.09 nM	4.700			
		2.84 nM	-0.650			
		0.80 nM	7.560			




					
59-0196	323.201				
59-0196		100.00 μ M			
		31.25 μ M			
		9.77 μ M			
		3.05 μ M			
		953.67 nM			
		298.02 nM			
		93.13 nM			
		29.10 nM			
		9.09 nM			
		2.84 nM			
		0.80 nM			
					
59-0197	323.201				
59-0197		100.00 μ M			
		31.25 μ M			
		9.77 μ M			
		3.05 μ M			
		953.67 nM			
		298.02 nM			
		93.13 nM			
		29.10 nM			
		9.09 nM			
		2.84 nM			
		0.80 nM			
					
59-0198	261.324				
59-0198		100.00 μ M			
		31.25 μ M			
		9.77 μ M			
		3.05 μ M			
		953.67 nM			
		298.02 nM			
		93.13 nM			
		29.10 nM			
		9.09 nM			
		2.84 nM			
		0.80 nM			
					
59-0199	291.35				
59-0199		100.00 μ M			
		31.25 μ M			

47 / 50

		9.09 nM		
		2.84 nM		
		0.80 nM		
	59-0203	292.338		
59-0203		100.00 uM		
		31.25 uM		
		9.77 uM		
		3.05 uM		
		953.67 nM		
		298.02 nM		
		93.13 nM		
		29.10 nM		
		9.09 nM		
		2.84 nM		
		0.80 nM		
	59-0204	344.389		
59-0204		100.00 uM		
		31.25 uM		
		9.77 uM		
		3.05 uM		
		953.67 nM		
		298.02 nM		
		93.13 nM		
		29.10 nM		
		9.09 nM		
		2.84 nM		
		0.80 nM		
	59-0205	318.782		
59-0205		100.00 uM		
		31.25 uM		
		9.77 uM		
		3.05 uM		
		953.67 nM		
		298.02 nM		
		93.13 nM		
		29.10 nM		
		9.09 nM		
		2.84 nM		
		0.80 nM		

						
59-0209	247.297					
59-0209		100.00 uM				
		31.25 uM				
		9.77 uM				
		3.05 uM				
		953.67 nM				
		298.02 nM				
		93.13 nM				
		29.10 nM				
		9.09 nM				
		2.84 nM				
		0.80 nM				
						
59-0210	297.376					
59-0210		100.00 uM				
		31.25 uM				
		9.77 uM				
		3.05 uM				
		953.67 nM				
		298.02 nM				
		93.13 nM				
		29.10 nM				
		9.09 nM				
		2.84 nM				
		0.80 nM				
						
59-8000	298.342					
59-8000		100.00 uM				
		31.25 uM				
		9.77 uM				
		3.05 uM				
		953.67 nM				
		298.02 nM				
		93.13 nM				
		29.10 nM				
		9.09 nM				
		2.84 nM				
		0.80 nM				

59-8001	255.273					
59-8001		100.00 uM				
		31.25 uM				
		9.77 uM				
		3.05 uM				
		953.67 nM				
		298.02 nM				
		93.13 nM				
		29.10 nM				
		9.09 nM				
		2.84 nM				
		0.80 nM				
59-8002	302.286					
59-8002		100.00 uM				
		31.25 uM				
		9.77 uM				
		3.05 uM				
		953.67 nM				
		298.02 nM				
		93.13 nM				
		29.10 nM				
		9.09 nM				
		2.84 nM				
		0.80 nM				
59-8003	270.288					
59-8003		100.00 uM				
		31.25 uM				
		9.77 uM				
		3.05 uM				
		953.67 nM				
		298.02 nM				
		93.13 nM				
		29.10 nM				
		9.09 nM				
		2.84 nM				
		0.80 nM				

		IC ₅₀ nM		
		29.10 nM		
		9.09 nM		
		2.84 nM		
		0.80 nM		
		301.364		
59-8013		100.00 μM		
59-8013		31.25 μM		
		9.77 μM		
		3.05 μM		
		953.67 nM		
		298.02 nM		
		93.13 nM		
		29.10 nM		
		9.09 nM		
		2.84 nM		
		0.80 nM		
		377.396		
59-8014		100.00 μM		
59-8014		31.25 μM		
		9.77 μM		
		3.05 μM		
		953.67 nM		
		298.02 nM		
		93.13 nM		
		29.10 nM		
		9.09 nM		
		2.84 nM		
		0.80 nM		
		285.299		
59-8015		100.00 μM		
59-8015		31.25 μM		
		9.77 μM		
		3.05 μM		

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US96/17019

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 31/54
US CL : 514/222.8

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/222.8

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
none

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS AND CAS ONLINE: compounds of the claims with bone, osteoporosis, hyperparathyroidism, periodontal, prosthetic, dental

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5,280,040 A (LABROO ET AL.) 18 January 1994.	1-29

Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means		
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

04 FEBRUARY 1997

Date of mailing of the international search report

20 FEB 1997

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231
Facsimile No. (703) 305-3230

Authorized officer

KIMBERLY JORDAN

Telephone No. (703) 308-1235